

Список используемой литературы

1. Mueller T, et al. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. *Clin Chim Acta* 2004;341:41-48.
2. Prontera C, et al. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. *Clin Chem Lab Med* 2004;42:37-44.
3. Pfister R, et al. Use of NT-proBNP in routine testing and comparison to BNP. *Eur J Heart Fail* 2004;6(3):289-293.
4. Seino Y, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. *Eur J Heart Fail* 2004;6(3):295-300.
5. Costello-Boerrigter LC, et al. NT-proBNP is superior to BNP in the detection of LV systolic dysfunction in the community. *J Cardiac Failure* 2004;10(4) Suppl. 4.
6. Fonseca C, et al. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. *Rev Port Cardiol* 2004;23(7-8):979-991.
7. Hunt PJ, et al. Immunoreactive amino terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. *Clin Endocrinol* 1997;47(3):287-296.
8. Troughton RW, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. *Lancet* 2000;355:1126-30.
9. Troughton RW, et al. Plasma Amino-Terminal B-Type Natriuretic Peptide Measured by Elecsys 2010 Assay in a Trial of Hormone-guided Treatment for Heart Failure. *Clin Chem* 2003;49, No. 7.
10. Remme WJ, Swedberg K et al. The European Society of Cardiology Task Force Report: Guidelines for the diagnosis and treatment of chronic heart failure. *European Heart Journal* 2001;22:1527-1560.
11. Richards AM, Nicholls GM, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction. *Circulation* 1998;97:1921-1929.
12. de Bold AJ. Atrial Natriuretic Factor: A Hormone Produced by the Heart. *Science* 1985;230:767-770.
13. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. *J Lab Clin Med* 1999;134:437-444.
14. de Bold AJ, Boerenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial extracts in rats. *Life Sci* 1981;28:89-94.
15. Epstein M, Loutzenhiser R, Friedland E, Aceto RM, Camargo MJF, Atlas SA. Relationship of Increased Plasma Atrial Natriuretic Factor and Renal Sodium Handling During Immersion-induced Central Hypervolemia in Normal Humans. *J Clin Invest* 1987;79:738-745.
16. The European Society of cardiology, Struthers AD. How to use natriuretic peptide levels for diagnosis and prognosis. *Eur Heart J* 1999;20:1374-1375.
17. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): a new marker for cardiac impairment. *Clin Endocrinol* 1997;47:287-296.

18. Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. *Eur Heart J* 1999;20:1736-1744.
19. Fisher C, et al. NT proBNP Predicts Prognosis in Patients with Chronic Heart Failure. *Heart* 2003;89:879-81.
20. James SK, et al. NT proBNP and other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients with Unstable Coronary Artery Disease. GUSTO IV Substudy. *Circulation* 2003;108:275-281.
21. Darbar D, Davidson NC, Gillespie N, Choy A-MJ, Lang CC, Shyr Y, et al. Diagnostic value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. *A J Cardiol* 1996;78:284-287.
22. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. *Lancet* 1998;351:9-13.
23. Yeo KT, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. *Clin Chim Acta* 2003;338:107-115.
24. Cowie MR, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. *Eur Heart J* 2003;24,1710-1718.
25. Nielsen LS, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnea. *Eur Heart J Fail* 2004;6:63-70.
26. Al-Barjas M, et al. How can the role of N terminal pro B Natriuretic Peptide (NT-proBNP) be optimised in heart failure screening? A prospective observational comparative study. *Eur Heart J Fail* 2004;3:51 Supplement 1.
27. Gustafsson F, et al. Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography. *Heart Drug* 2003;3:141-146.
28. Albers S, et al. *Clin Chem Lab Med* 2006;44(1):80-85.

29. Januzzi JL, et al. *European Heart Journal Advance Access published November 17, 2005.*

30. Инструкция производителя реагентов
31. Кишкун А.А. - «Клинические лабораторные исследования», 2008г.
32. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. *Scand J Clin Lab Invest* 1956;8:174.
33. Ruoslahti E, Engvall E, Kessler MJ. Chemical properties of alpha-fetoprotein. In: Herberman RB, McIntire KR, eds. *Immunodiagnosis of Cancer*. New York: Marcel Dekker, Inc.,1979:101-17.
34. Ruoslahti E, Seppala M. Studies of carcino-fetal proteins: physical and chemical properties of human alpha-fetoprotein. *Int J Cancer* 1971;7:218-25.
35. Tatarinov YS. Detection of embryo-specific alpha-globulin in the blood serum of patients with primary liver tumors. *Vopr Med Khim* 1964;10:90-1.
36. Silver HKB, Gold P, Feder S, et al. Radioimmunoassay for human alpha-fetoprotein. *Proc Natl Acad Sci USA* 1973;70(2):526-30.
37. Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. *Cancer* 1974; 34:1510-5.
38. Kohn J, Orr AH, McElwain TJ, et al. Serum-alpha-fetoprotein in patients with testicular tumours. *Lancet* 1976;2:433-6.

39. Abelev GI. Alpha-fetoprotein as a model for studying reexpression of embryonic antigens in neoplasia. In: Herberman RB, McIntire KR, eds. *Immunodiagnosis of Cancer*. New York: Marcel Dekker, Inc., 1979: 76-101.
40. Scardino PT, Cox HD, Waldmann TA, et al. The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. *J Urol* 1977;118:994-9.
41. Bosl GJ, Lange PH, Fraley EE, et al. Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. *Cancer* 1981;47:328-32.
42. Lange PH, McIntire KR, Waldmann TA, et al. Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. *N Engl J Med* 1976;295(22):1237-40.
43. Javadpour N, McIntire KR, Waldmann TA. Human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma. *Cancer* 1978;42:2768-72.
44. Report from the Medical Research Council Working Party on Testicular Tumours. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. *Lancet* 1985:8-11.
45. Perlin E, Engeler JE, Edson M, et al. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. *Cancer* 1976;37:215-9.
46. Wepsic HT. Alpha-fetoprotein: its quantitation and relationship to neoplastic disease. In: Kirkpatrick AM, Nakamura RM, eds. *Alpha-fetoprotein, laboratory procedures and clinical applications*. New York: Masson Publishing USA Inc., 1981:115-29.
47. McIntire KR, Waldmann TA, Moertel CG, et al. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. *Cancer Res* 1975;35:991-6.
48. Chen DS, Sung JL. Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. *Cancer* 1979;44:984-92.
49. Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. *Lancet* 1977:1323-32.
50. Second Report of the U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects. Amniotic-fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. *Lancet* 1979:651-62.
51. Haddow JE, Kloza EM, Smith DE, et al. Data from an alpha-fetoprotein pilot screening program in Maine. *Obstet Gynecol* 1983;62(5):556-60.
52. Brock DJH. The prenatal diagnosis of neural tube defects. *Obstet Gynecol Surv* 1976;31(1):32-40.
53. Main DM, Mennuti MT. Neural tube defects: issues in prenatal diagnosis and counselling. *Obstet Gynecol* 1986;67(1):1-16.
54. Adams MJ, Windham GC, James LM, et al. Clinical interpretation of maternal serum alpha-fetoprotein concentrations. *Am J Obstet Gynecol* 1984;148(3):241-54.

55. American Society of Human Genetics policy statement for maternal serum alpha-fetoprotein screening programs and quality control for laboratories performing maternal serum and amniotic fluid alpha-fetoprotein assays. *Am J Hum Genet* 1987;40:75-82.
56. Cuckle HS, Nanchahal K, Wald NJ. Maternal serum alpha-fetoprotein and ethnic origin. *Br J Obstet Gynaecol* 1987;94:1111-2.
57. Crandall BF, Lebherz TB, Schroth PC, et al. Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight. *Clin Chem* 1983;29(3):531-3.
58. Milunsky A, Alpert E, Kitzmiller JL, et al. Prenatal diagnosis of neural tube defects. VIII. The importance of serum alpha-fetoprotein screening in diabetic pregnant women. *Am J Obstet Gynecol* 1982;142:1030-2.
59. Baumgarten A, Robinson J. Prospective study of an inverse relationship between maternal glycosylated hemoglobin and serum alpha-fetoprotein concentrations in pregnant women with diabetes. *Am J Obstet Gynecol* 1988;159(1):77-81.
60. Palomaki GE, Knight GJ, Kloza EM, et al. Maternal weight adjustment and low serum alpha-fetoprotein values. *Lancet* 1985:468.
61. Wald NJ, Cuckle H, Boreham J, et al. Maternal serum alpha-fetoprotein and diabetes mellitus. *Br J Obstet Gynaecol* 1979;86:101-5.
62. Crandall BF. Second trimester maternal serum screening to identify neural tube defects. In: Kirkpatrick AM, Nakamura RM, eds. *Alpha-fetoprotein, laboratory procedures and clinical applications*. New York: Masson Publishing USA Inc., 1981:93-105
63. Seppala M, Rapola J, Huttunen NP, et al. Congenital nephrotic syndrome: prenatal diagnosis and genetic counselling by estimation of amniotic fluid and maternal serum alpha-fetoprotein. *Lancet* 1976:123-5.
64. Seppala M. Increased alpha fetoprotein in amniotic fluid associated with a congenital esophageal atresia of the fetus. *Obstet Gynecol* 1973;42(4):613-4.
65. Palomaki GE, Hill LE, Knight GJ, et al. Second-trimester maternal serum alpha-fetoprotein levels in pregnancies associated with gastroschisis and omphalocele. *Obstet Gynecol* 1988;71(6):906-9.
66. Wald N, Barker S, Cuckle H, et al. Maternal serum alpha-fetoprotein and spontaneous abortion. *Br J Obstet Gynaecol* 1977;84:357-62.
67. Brock DJH, Barron L, Duncan P, et al. Significance of elevated mid-trimester maternal plasma-alpha-fetoprotein values. *Lancet* 1979:1281-2.
68. Nelson LH, Bensen J, Burton BK. Outcomes in patients with unusually high maternal serum alpha-fetoprotein levels. *Am J Obstet Gynecol* 1987;157(3):572-6.
69. Redford DHA, Whitfield CR. Maternal serum alpha-fetoprotein in twin pregnancies uncomplicated by neural tube defect. *Am J Obstet Gynecol* 1985;152(5):550-3.
70. Davenport DM, Macri JN. The clinical significance of low maternal serum alpha-fetoprotein. *Am J Obstet Gynecol* 1983;146(6):657-61.
71. US Department of Labor, Occupational Safety and Health Administration, 29 CFR Part 1910.1030, Bloodborne pathogens.
72. World Health Organization. *Laboratory Biosafety Manual*. 3rd ed. Geneva: World Health Organization; 2004

73. Horacek I, Pepperell RJ, Hay DL, et al. Detection of fetomaternal hemorrhage by measurement of maternal serum-alpha-fetoprotein. *Lancet* 1976;200.
74. Clinical and Laboratory Standards Institute. Maternal Serum Screening; Approved Standard – Second Edition. CLSI document I/LA25-A2. Wayne, PA: CLSI; 2011.
75. Sherwin JE ed. National Academy of Clinical Biochemistry: Laboratory Medicine Practice Guidelines. Maternal-fetal risk assessment and reference values in pregnancy. Washington, DC: AACC Press, 2006:24.
76. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. *Clin Chem* 1988;34(1):27-33.
77. Bradley LA, Palomaki GE, and McDowell GA. ACMG Standards and Guidelines: technical standards and guidelines: prenatal screening for open neural tube defects. *Genetics in Medicine* 2005;7(5):355-69.
78. Fraser CG. Biological Variation: From Principles to Practice. Washington, DC: AACC Press, 2001:71-8.
79. Trape J, Botargues JM, Porta F, et al. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. *Clin Chem* 2003;49:1209-11.
80. National Committee for Clinical Laboratory Standards (NCCLS). Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition. NCCLS Document EP5-A2. Wayne, PA: NCCLS; 2004
81. Clinical and Laboratory Standards Institute. User Verification of Performance for Precision and Trueness; Approved Guideline – Second Edition. CLSI document EP15-A2. Wayne, PA: CLSI; 2005.
82. National Committee for Clinical Laboratory Standards (NCCLS). Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. NCCLS Document EP6-A. Wayne, PA: NCCLS; 2003.
83. National Committee for Clinical Laboratory Standards (NCCLS). Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. NCCLS Document EP17-A. Wayne, PA: NCCLS; 2004.
84. Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition. CLSI Document EP7-A2. Wayne, PA: CLSI; 2005.
85. Neurath AR, Kent SB, Strick N, et al. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. *Cell* 1986;46:429-36.
86. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *N Engl J Med* 1980;303:833-41.
87. Krugman S, Giles JP. Viral hepatitis, type B (MS-2-Strain)- further observations on natural history and prevention. *N Engl J Med* 1973;288:755-60.
88. Krugman S, Overby LR, Mushahwar IK, et al. Viral hepatitis, type B studies on natural history and prevention re-examined. *N Engl J Med* 1979;300:101-6.
89. Perrillo RP, Aach RD. The clinical course and chronic sequelae of hepatitis B virus infection. *Seminars in Liver Disease* 1981;1:15-25.

90. CDC. A comprehensive immunization strategy to eliminate transmission of Hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents. *MMWR* 2005;54(RR-16):1-23.
91. Centers for Disease Control and Prevention. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta, GA: 2005.
92. Koziel MJ, Siddiqui A. Hepatitis B virus and hepatitis delta virus. In: Mandell GL, Bennett JE, Dolin R, eds. *Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases*. 6th ed. New York, NY: Elsevier/Churchill Livingstone; 2005:1864-90.
93. Schroff RW, Foon KA, Beatty SM, et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. *Cancer Res* 1985;45:879-85.
94. Meyer JC. Laboratory Diagnosis of Syphilis. *Curr Probl Dermatol*. 1996; 24: 1-11.
95. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Fourth Edition. CLSI Document M29-A4. Wayne, PA: CLSI; 2014.
96. Engvall E, Perlman P. Enzyme-Linked Immunosorbent Assay (ELISA) Quantitative Assay of Immunoglobulin G. *Immunochemistry* 1971;8:871-874.
97. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989;244:359-362.
98. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 1989;244:362-364.
99. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N Engl J Med* 1989;321:1494-1500.
100. Esteban JI, Viladomiu L, Gonzalez A, et al. Hepatitis C virus antibodies among risk groups in Spain. *Lancet* 1989;ii:294-297.
101. Van der Poel CL, Lelie PN, Choo QL, et al. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. *Lancet* 1989;ii:297-298.
102. Esteban JI, Gonzalez A, Hernandez JM, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. *N Engl J Med* 1990;323:1107-1112.
103. Miyamura T, Saito I, Katayama T, et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for post-transfusion hepatitis. *Proc Natl Acad Sci USA* 1990;87:983-987.
104. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. *N Engl J Med* 1991;325:1325-1329.

105. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. *JAMA* 1990;264:2231-2235.
106. Choo QL, Weiner AJ, Overby LR, et al. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. *Br Med J* 1990;46:423-441.
107. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. *Gastroenterology* 1983;85:439-462.
108. Gitnick G. Non-A, non-B hepatitis: etiology and clinical course. *Ann Rev Med* 1984;35:265-278.
109. Wick MR, Moore S, Taswell HF. Non-A, non-B hepatitis associated with blood transfusion. *Transfusion* 1985;25:93-101.
110. Hollinger FB. Non-A, Non-B Hepatitis Viruses. In: Fields BN, Knipe DN, editors. *Virology*. New York: Raven Press, 1990:2239-2273.
111. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. *Lancet* 1991;338:1040-1041.
112. Donahue JG, Munoz A, Ness PM, et al. The declining risk of posttransfusion hepatitis C virus infection. *N Engl J Med* 1992;327:369-373.
113. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Seminars in Liver Disease* 1995;15:41-63.
114. SAS Institute Inc. The MIXED Procedure. In: SAS Technical Report P-229, SAS/STAT Software: Changes and Enhancements, Release 6.07. Cary, NC: SAS Institute Inc, 1992:289-366.
115. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983;220:868-71.
116. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science* 1984;224:497-500.
117. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 1984;224:500-3.
118. Leitner T. Genetic subtypes of HIV-1. In: Myers G, Korber BT, Foley BT et al., editors. *Human Retroviruses and AIDS* 1996. Los Alamos, NM: Los Alamos National Laboratory, 1996:III-28-III-40. (Available on-line at <http://hiv-web.lanl.gov>)
119. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. In: Kuiken CL, Foley B, Hahn B, et al., editors. *Human Retroviruses and AIDS* 1999. Los Alamos, NM: Los Alamos National Laboratory; 1999:492-505. (Available on-line at <http://hiv-web.lanl.gov>)
120. Clavel F, Guetard D, Brun-Vezinet F et al. Isolation of a new human retrovirus from West African patients with AIDS. *Science* 1986;233:343-6.
121. Clavel F. HIV-2, the West African AIDS virus. *AIDS* 1987;1:135-40.

122. Schochetman G, George JR, editors. AIDS Testing: A Comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues. 2nd ed. New York: NY Springer-Verlag; 1994.
123. Sarngadharan MG, Popovic M, Bruch L, et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. *Science* 1984;224:506-8.
124. Jackson JB, Kwok SY, Sninsky JJ, et al. Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals. *J Clin Microbiol* 1990;28:16-9.
125. Simon F, Mauciere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nature Medicine* 1998;4:1032-7.
126. Ayouba A, Souquieres S, Njinku B, et al. HIV-1 group N among HIV-1-seropositive individuals in Cameroon. *AIDS* 2000;14:2623-5.
127. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. *J Virology* 1994;68(3):1581-5.
128. Peeters M, Gueye A, Mboup S, et al. Geographical distribution of HIV-1 group O viruses in Africa. *AIDS* 1997;11:493-8.
129. Hunt JC, Golden AM, Lund JK, et al. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from Equatorial Guinea. *AIDS Res Hum Retroviruses* 1997;13(12):995-1005.
130. Hackett J Jr, Zekeng L, Brennan CA, et al. Genetic analysis of HIV type 1 group O p24gag sequences from Cameroon and Equatorial Guinea. *AIDS Res Hum Retroviruses* 1997;13(13):1155-8.
131. Vanden Haesevelde M, Decourt J, De Leys RJ, et al. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. *J Virology* 1994;68(3):1586-96.
132. Hampl H, Sawitzky D, Stoffler-Meilicke M, et al. First case of HIV-1 subtype O infection in Germany. *Infection* 1995;23:369-70.
133. Loussert-Ajaka I, Chaix M-L, Korber B, et al. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. *J Virology* 1995;69:5640-9.
134. Soriano V, Gutierrez M, Garcia-Lerma G et al. First case of HIV-1 group O infection in Spain. *Vox Sang* 1996;71:66.
135. Rayfield MA, Sullivan P, Bondea CI, et al. HIV-1 group O virus identified for the first time in the United States. *Emerging Infectious Diseases* 1996;2:209-12.
136. Sullivan PS, Do AN, Robbins K, et al. Surveillance for variant strains of HIV: subtype G and group O HIV-1. *JAMA* 1997;278:292.
137. Peeters, M. Recombinant HIV sequences: their role in the global epidemic. In: Kuiken C, Foley B, Hahn B, et al., editors. *HIV Sequence Compendium 2000*. Los Alamos, NM: Los Alamos National Laboratory, 2000:54-73. (Available on-line at <http://hiv-web.lanl.gov>)
138. Montavon C, Toure-Kane C, Liegeois F, et al. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. *J Acquir Immune Defic Syndr* 2000;23:363-74.
139. Brennan CA, Lund JK, Golden A, et al. Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. *AIDS* 1997;11:1823-32.

140. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. *J Virology* 2000;74:10498-507.
141. Hussein M, Abebe A, Pollakis G, et al. HIV-1 subtype C in commercial sex workers in Addis Ababa, Ethiopia. *J Acquir Immune Defic Syndr* 2000;23:120-7.
142. Van Harmelen JH, Van Der Ryst E, Loubser AS, et al. A predominately HIV type 1 subtype C-restricted epidemic in South African urban populations. *AIDS Res Hum Retroviruses* 1999;15:395-8.
143. Couturier E, Damond F, Roques P, et al. HIV-1 diversity in France, 1996-1998. *AIDS* 2000;14:289-96.
144. Fransen K, Buve A, Nkengasong JN, et al. Longstanding presence in Belgians of multiple non-B HIV-1 subtypes. *Lancet* 1996;347:1403.
145. Weniger BG, Takebe Y, Ou C, et al. The molecular epidemiology of HIV in Asia. *AIDS* 1994;8(S2):S13-28.
146. Russell KL, Carcamo C, Watts DM, et al. Emerging genetic diversity of HIV-1 in South America. *AIDS* 2000;14:1785-91.
147. Tanuri A, Swanson P, Devare S, et al. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. *J Acquir Immune Defic Syndr* 1999;20:60-6.
148. Marlink RG, Ricard D, M'Boup S, et al. Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2). *AIDS Res Hum Retroviruses* 1988;4:137-48.
149. Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. *AIDS* 1993;7:1411-7.
150. Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. *Lancet* 1994;343:943-6.
151. DeCock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. *JAMA* 1993;270:2083-6.
152. Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. *J Virology* 1994;68:7433-47.
153. Yamaguchi J, Devare SG, Brennan CA. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. *AIDS Res Hum Retroviruses* 2000;16:925-30.
154. Dawson GJ, Heller JS, Wood CA, et al. Reliable detection of individuals seropositive for the human immunodeficiency virus (HIV) by Competitive Immunoassays using *Escherichia coli*-expressed HIV structural proteins. *J Infect Dis* 1988;157:149-55.
155. Montagnier L, Clavel F, Krust B, et al. Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. *Virology* 1985;144:283-9.
156. Barin F, McLane MF, Allan JS, et al. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. *Science* 1985; 228:1094-6.
157. Schulz TF, Aschauer JM, Hengster P, et al. Envelope gene-derived recombinant peptide in the serodiagnosis of human immunodeficiency virus infection. *Lancet* 1986;2:111-2.

158. Allan JS, Coligan JE, Barin F, et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. *Science* 1985;228:1091-4.
159. HIV-1/HIV-2/SIV Complete genomes. In: Kuiken CL, Foley B, Freed E, et al., editors. *HIV Sequence Compendium 2002*. Los Alamos, NM: Los Alamos National Library; 2002:377-480.
160. Yamaguchi J, Bodelle P, Kaptue L, et al. Near full-length genomes of 15 HIV type 1 group O isolates. *AIDS Res Hum Retroviruses* 2003;19:979-88.
161. Hunt JC, Johnson-Paepke J, Boardway K, et al. Discrimination between HIV-1 and HIV-2 seropositive individuals using mouse monoclonal antibodies directed to HIV transmembrane proteins. *AIDS Res Hum Retroviruses* 1990;6:883-98.
162. Barin F, M'Boup S, Denis F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. *Lancet* 1985;2:1387-9.
163. Kanki PJ, Barin F, M'Boup S, et al. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). *Science* 1986;232:238-43.
164. Kanki PJ, M'Boup S, Ricard D, et al. Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa. *Science* 1987;236:827-31.
165. Clavel F, Guyader M, Guetard D, et al. Molecular cloning and polymorphism of the human immune deficiency virus type 2. *Nature* 1986;324:691-5.
166. Cot M, Poulain M, Delagneau JF et al. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis. *AIDS Res Hum Retroviruses* 1988;4:239-41.
167. Simon F, Cot M, Lesager C, et al. Differentiation between HIV-1 and HIV-2 infection by radioimmunoprecipitation and synthetic peptides in double reactive sera. *AIDS* 1989;3:401-4.
168. Norrby E, Biberfeld G, Chiodi F, et al. Discrimination between antibodies to HIV and to related retroviruses using site-directed serology. *Nature* 1987;329:248-50.
169. Gurtler LG, Zekeng L, Simon F, et al. Reactivity of five anti-HIV-1 subtype O specimens with six different anti-HIV screening ELISAs and three immunoblots. *J Virol Methods* 1995;51:177-84.
170. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. *Lancet* 1994;343:1393-4.
171. Devare SG, Desai Sm, Dawson GJ, et al. Diagnosis and monitoring of HIV-1 and HIV-2 infection. In: Khan NC, Melnick JL, editors. *Human Immunodeficiency Virus: Innovative Techniques for Isolation and Identification (Monographs in Virology, vol.18)*. Basel: S Karger; 1990; 18:105-21.
172. Kessler HA, Blaauw B, Spear J, et al. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. *JAMA* 1987;258:1196-9.
173. Phair JP. Human immunodeficiency virus antigenemia. *JAMA* 1987;258:1218.9

174. Allain J-P, Laurian Y, Paul DA, et al. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. *Lancet* 1986;2(8518):1233-6.
175. Kenny C, Parkin J, Underhill G, et al. HIV antigen testing. *Lancet* 1987;1(8532):565-6.
176. Wall RA, Denning DW, Amos A. HIV antigenaemia in acute HIV infection. *Lancet* 1987;1(8532):566.
177. Stute R. HIV antigen detection in routine blood donor screening. *Lancet* 1987;1(8532):566.
178. Goudsmit J, De Wolf F, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. *Lancet* 1986;2(8500):177-80.
179. Von Sydow M, Gaines H, Sonnerberg A, et al. Antigen detection in primary HIV infection. *Brit Med J* 1988;296:238-40.
180. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), November 2004. <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073972.htm>
Accessed July 01, 2013.
181. Box GEP, Hunter WG, Hunter JS. *Statistics for experimenters; an introduction to design, data analysis, and model building*. New York, NY: John Wiley & Sons, Inc, 1978:510-39, 571-83.
182. SAS Institute, Inc. SAS Technical Report P-229, SAS/STAT Software: Changes and enhancements, Release 6.07. Cary, NC: SAS Institute, 1992:289-366.
183. Markle HV. Cobalamin. *Crit Rev Clin Lab Sci* 1996;33(4):247-356.
184. Carmel R, Herbert V. Deficiency of vitamin B12-binding alpha globulin in two brothers. *Blood* 1969;33(1):1-12.
185. Hakami N, Neiman PE, Canellos GP, et al. Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. *New Engl J Med* 1971;285(21):1163-1170.
186. Hall CA. Congenital disorders of vitamin B12 transport and their contributions to concepts. II. *Yale J Biol Med* 1981;54:485-495.
187. Li N, Rosenblatt DS, Seetharam B. Nonsense mutations in human transcobalamin II deficiency. *Biochem Biophys Res Commun* 1994;204(3):1111-1118.
188. Bjorksten KS, Thorell L-H, Nexo E. Circadian variation of plasma cobalamin, transcobalamin-bound cobalamin and unsaturated binding capacity of transcobalamin and haptocorrin in healthy elderly. *J. Affective Disorders* 1995;36:37-42.
189. Nexo E, Hvas A-M, Bleie O, et al. Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. *Clin Chem* 2002;48(10):1768-1771.

190. Lindenbaum J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. *Am J Hematol* 1990;34:99-107.
191. Green R. Screening for vitamin B sub 12 deficiency: caveat emptor. *Ann Intern Med* 1996;124(5):509-511.
192. England JM, Linnell JC. Problems with the serum vitamin B12 assay. *Lancet* 1980:1072-1074.
193. Matchar DB, McCrory DC, Millington DS, et al. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. *Am J Med Sci* 1994;308(5):276-283.
194. Valente E, Scott JM, Ueland P-M, et al. Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B12 status in the elderly. *Clin Chem* 2011;57(6):856-863.
195. Tisman G, Vu T, Amin J, et al. Measurement of red blood cell-vitamin B12: a study of the correlation between intracellular B12 content and concentrations of plasma holotranscobalamin II. *Am J Hematol* 1993;43:226-229.
196. Herbert V, Fong W, Gulle V, et al. Low holotranscobalamin II is the earliest serum marker for subnormal vitamin B12 (cobalamin) absorption in patients with AIDS. *Am J Hematol* 1990;34:132-139.
197. Nexø E, Christensen A-L, Hvas A-M, et al. Quantification of holotranscobalamin, a marker of vitamin B12 deficiency. *Clin Chem* 2002;48(3):561-562.
198. Ulleland M, Eilertsen I, Quadros EV, et al. Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum. *Clin Chem* 2002;48(3):526-532.
199. Obeid R, Jouma M, Herrmann W. Cobalamin status (holotranscobalamin, methylmalonic acid) and folate as determinants of homocysteine concentration. *Clin Chem* 2002;48(11):2064-2065.
200. Herrmann W, Obeid R, Schorr H, et al. Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. *Clin Chem Lab Med* 2003;41(11):1478-1488.
201. Herrmann W, Schorr H, Obeid R, et al. Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. *Am J Clin Nutr* 2003;78:131-136.
202. Lloyd-Wright Z, Hvas A-M, Moller J, et al. Holotranscobalamin as an indicator of dietary vitamin B12 deficiency. *Clin Chem* 2003;49(12):2076-2078.
203. Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. *J Clin Pharmacol* 1999;39:327-348.
204. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocr Rev* 2003;24(2):152-182.
205. Schneider HP. Androgens and antiandrogens. *Ann N Y Acad Sci* 2003;997:292-306.

206. Haymond S, Gronowski AM. Reproductive related disorders. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. St. Louis, Missouri: Elsevier Inc.; 2006:2132-2134.
207. Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. *Am J Obstet Gynecol* 2004;191(3):713-717.
208. Rieu M, Reznik Y, Vannetzel JM, et al. Testicular steroidogenesis in adult men with human chorionic gonadotropin-producing tumors. *J Clin Endocrinol Metab* 1995;80(8):2404-2409.
209. Marks V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. *Clin Chem* 2002;48(11):2008-2016.
210. Shackleton CHL. Steroid synthesis and catabolism in the fetus and neonate. In: Makin HLJ, editor. *Biochemistry of Steroid Hormones*. 2nd ed. Oxford, UK: Blackwell Scientific Publications; 1984:441-477.
211. Kojima S, Yanaihara T, Nakayama T. Serum steroid levels in children at birth and in early neonatal period. *Am J Obstet Gynecol* 1981;140(8):961-965.
212. National Committee for Clinical Laboratory Standards (NCCLS). *Interference Testing in Clinical Chemistry; Approved Guideline*. NCCLS Document EP7-A. Wayne, PA: NCCLS; 2002.
213. Pierce JG, Parsons TF. Glycoprotein Hormones: Structure and Function. *Annu Rev Biochem* 1981;50:465-495.
214. Shome B, Parlow AF. Human Follicle Stimulating Hormone (hFSH): First Proposal for the Amino Acid Sequence of the α -subunit and First Demonstration of its α -subunit identity with an α -subunit of human Luteinizing Hormone (hLH α) *J Clin Endocrinol Metab* 1974; 39:199-202.
215. Sairam MR, Li CH. Human Pituitary Thyrotropin. Isolation and Chemical Characterization of its Subunits. *Biochem Biophys Res Commun* 1973; 51:336-342.
216. Vaitukaitis JL, Ross GT, Braunstein GD, et al. Gonadotropins And Their Subunits: Basic and Clinical Studies. *Recent Prog Horm Res* 1976; 32:289-331.
217. Bishop WH, Nureddin A, Ryan RJ. Pituitary Luteinizing and Follicle Stimulating Hormones. In: Parons JA, editor. *Peptide Hormones*. Baltimore: University Park Press, 1976; 273-298.
218. Keutmann HT, Williams RM, Ryan RJ. Structure of Human Luteinizing Hormone Beta Subunit: Evidence for a Related Carboxyl-Terminal Sequence Among Certain Peptide Hormones. *Biochem Biophys Res Commun* 1979; 90:842-848.
219. Daughaday WH. The Adenohypophysis. In: Wilson JD and Foster DW, editors. *Williams Textbook of Endocrinology*. Philadelphia: Saunders, 1985
220. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle Stimulating Hormones. *Science* 1971; 173:1036-1038.
221. Harris GW, Naftolin F. The Hypothalamus and Control of Ovulation. *Br Med Bull* 1970; 26:3-9.

222. Knobil E. The Neuroendocrine Control of the Menstrual Cycle. *Recent Prog Horm Res* 1980; 36:53-88.
223. Ross GT. Disorders of the Ovary and Female Reproductive Tract. In: Wilson JD, Foster DW, editors. *Williams Textbook of Endocrinology*. Philadelphia: WB Saunders Co. 1985:206-258.
224. Vande Wiele RL, Bogumil J, Dyrenfurth I, et al. Mechanisms Regulating the Menstrual Cycle in Women. *Recent Prog Horm Res* 1970; 26:63-103.
225. Bonnar J. Gynaecology and Obstetrics; The Hypothalamus and Reproductive Function. In: Scott RB and Walker RM, editors. *The Medical Annual*. Bristol (England): J Wright & Sons 1973
226. Griffin JE, Wilson JD. Disorders of the Testes and Male Reproductive Tract. In: Wilson JD and Foster DW, editors. *Williams Textbook of Endocrinology*. Philadelphia: Saunders 1985; 259-311.
227. Beastall GH, et al. Assays for Follicle Stimulating Hormone and Luteinizing Hormone: Guidelines for the Provision of a Clinical Biochemistry Service. *Ann Clin Biochem* 1987;24:246-262.
228. Judd HL. Hormonal Dynamics Associated with the Menopause. *Clin Obstet Gynecol* 1976;19:775-788.
229. Kletzky OA, Davajan V. Differential Diagnosis of Secondary Amenorrhea. In: Mishell DR Jr, Brenner PF, editors. *Management of Common Problems in Obstetrics and Gynecology*. Oradell: Medical Economics Books 1983; 352-356.
230. Lachelin G. The Polycystic Ovary Syndrome. In: Studd J, editor. *Prog Obstet Gynecol*. Edinburgh: Churchill Livingstone 1984; 290-301.
231. Franchimont P. Human Gonadotropin Secretion in Male Subjects. In: James VHT, Serio M and Martini L, editors. *The Endocrine Function of the Human Testis*. New York: Academic Press, 1973:439-458.
232. Marshall JC. Investigative Procedures. Pituitary-Gonadal Relations in Infancy. *J Clin Endocrinol Metab* 1975; 4:545-551.
233. Clinical and Laboratory Standards Institute (CLSI). *Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions; Approved Guideline—Third Edition*. CLSI Document C24-A3. Wayne, PA: CLSI; 2006.
234. Clinical and Laboratory Standards Institute. *Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition (Interim Revision)*. CLSI Document EP9-A2-IR. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
235. DeGroot LJ, Larsen PR, Refetoff S, Stanbury JB. Transport of Thyroid Hormone and Cell Uptake. In: *The Thyroid and Its Diseases*. New York: Wiley and Sons, 1984;62-66.
236. Wahner HW, Gorman CA. Interpretation of Serum Tri-Iodothyronine Levels Measured by the Sterling Technic. *N Engl J Med* 1971;284:225-230.
237. Marsden P, McKerron CG. Serum Triiodothyronine Concentration in the Diagnosis of Hyperthyroidism. *Clin Endocrinol* 1975;4:183-189.
238. Ivy HK, Washner HW, Gorman CA. Triiodothyronine (T3) Toxicosis: Its Role in Graves' Disease. *Arch Intern Med* 1971;128:529-534.

239. Hollander CS, Mitsuma T, Nihei N, Shenkman L, Burday SZ, Blum M. Clinical and Laboratory Observations in Cases of Triiodothyronine Toxicosis Confirmed by Radioimmunoassay. *Lancet* 1972;1:609-611.
240. Hollander CS, Mitsuma T, Shenkman L, Stevenson C, Pineda G, Silva E. T₃ Toxicosis in an Iodine-Deficient Area. *Lancet* 1972;2:1276-1278.
241. Ermans AM. Disorders of Iodine Deficiency. In: Ingbar SH, Braverman LE, editors. *The Thyroid* (5th Ed.). Philadelphia: JB Lippincott Co., 1986:705-721.
242. Kaplan MM, Larsen PR, Crantz FR, Dzau VJ, Rossing TH, Haddow JE. Prevalence of Abnormal Thyroid Function Test Results in Patients with Acute Medical Illnesses. *Am J Med* 1982;72:9-16.
243. Oppenheimer JH. Thyroid Function Tests in Nonthyroidal Disease. *J Chronic Dis* 1982;35:697-701.
244. Abuid J, Larsen PR. Triiodothyronine and Thyroxine in Hyperthyroidism: Comparison of the Acute Changes During Therapy with Antithyroid Agents. *J Clin Invest* 1974;54:201-208.
245. Felig P, Baxter JD, Broadus AE, Frohman LA, editors. *Endocrinology and Metabolism* (2nd Ed.). New York: McGraw-Hill Book Co., 1987
246. Abraham GE, Odell WD, Swerdloff RS, Hopper K. Simultaneous radioimmunoassay of plasma FSH, LH, progesterone, 17-hydroxyprogesterone, and estradiol-17 β during the menstrual cycle. *J Clin Endocr.* 1972;34:312-318.
247. Strauss JF III, Hsueh AJW. Ovarian hormone synthesis. In: DeGroot LJ, Jameson JL, et al. eds. *Endocrinology*. Vol 3. 4th ed. Philadelphia: WB Saunders Co., 2001. 2043-2052.
248. Weigel NL, Rowan BG. Estrogen and progesterone action. In: DeGroot LJ, Jameson JL, et al. eds. *Endocrinology*. Vol 3. 4th ed. Philadelphia: WB Saunders Co., 2001. 2053-2060.
249. Erickson GF. Folliculogenesis, ovulation, and luteogenesis. In: DeGroot LJ, Jameson JL, et al. eds. *Endocrinology*. Vol 3. 4th ed. Philadelphia: WB Saunders Co., 2001. 2061-2071.
250. Hertig AT, Livingstone RG. Spontaneous, threatened and habitual abortion: their pathogenesis and treatment. *N Eng J Med.* 1944;230: 797-806.
251. Aedo AR, Nunez M, Landgren B-M, et al. Studies on the pattern of circulating steroids in the normal menstrual cycle. *Acta Endocrinol.* 1977;84:320-332.
252. Landgren B-M, Uden A-L, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. *Acta Endocrinol.* 1980;94:89-98.
253. Erickson GF. Normal ovarian function. *Clin Obstet Gynecol.* 1978; 21:31-52.
254. Veldhuis JD, Christiansen E, Evans WS, et al. Physiological profiles of episodic progesterone release during the midluteal phase of the human menstrual cycle: analysis of circadian and ultradian rhythms, discrete pulse properties, and correlations with simultaneous luteinizing hormone release. *J Clin Endocrinol Metab.* 1988;66:414-421.
255. Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. *J Clin Invest.* 1984;73:1638-1647.

256. Laufer N, Navot D, Schenker JG. The pattern of luteal phase plasma progesterone and estradiol in fertile cycles. *Am J Obstet Gynecol.* 1982;143:808-813.
257. Winkel P, Gaede P, Lyngbye J. Method for monitoring plasma progesterone concentrations in pregnancy. *Clin Chem.* 1976;22:422-428.
258. Buster JE, Abraham GE. The applications of steroid hormone radioimmunoassays to clinical obstetrics. *Obstet Gynecol.* 1975;46:489-499.
259. Israel R, Mishell DR, Stone SC, et al. Single luteal phase serum progesterone assay as an indicator of ovulation. *Am J Obstet Gynecol.* 1972;112:1043-1046.
260. Petsos P, Chandler C, Oak M, et al. The assessment of ovulation by a combination of ultrasound and detailed serial hormone profiles in 35 women with long-standing unexplained infertility. *Clin Endocrinol.* 1985;22:739-751.
261. Abdulla U, Diver MJ, Hipkin LJ, Davis JC. Plasma progesterone levels as an index of ovulation. *Br J Obstet Gynaecol.* 1983;90:543-548.
262. Rosenberg SM, Luciano AA, Riddick DH. The luteal phase defect: the relative frequency of, and encouraging response to, treatment with vaginal progesterone. *Fertil Steril.* 1980;34:17-20.
263. Tho PT, Byrd JR, McDonough PG. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion. *Fertil Steril.* 1979;32:389-395.
264. Hernandez Horta JL, Gordillo Fernandez J, Soto de Leon B, Cortes-Gallegos V. Direct evidence of luteal insufficiency in women with habitual abortion. *Obstet Gynecol.* 1977;49:705-708.
265. Jones GS. The physiology of menstruation and the corpus luteum function. *Int J Fertil.* 1986;31:143-147.
266. Soules MR, McLachlan RI, Ek M, et al. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle. *J Clin Endocrinol Metab.* 1989;69:804-812.
267. Schweiger U, Laessle R, Schweiger M, et al. Caloric intake, stress and menstrual function in athletes. *Fertil Steril.* 1988;49:447-450.
268. Witt BR, Wolf GC, Wainwright CJ, et al. Relaxin, CA-125, progesterone, estradiol, Schwangerschaft protein, and human chorionic gonadotropin as predictors of outcome in threatened and nonthreatened pregnancies. *Fertil Steril.* 1990;53:1029-1036.
269. Matthew CP, Coulson PB, Wild RA. Serum progesterone levels as an aid in the diagnosis of ectopic pregnancy. *Obstet Gynecol.* 1986;68:390-394.
270. Hubinont CJ, Thomas C, Schwers JF. Luteal function in ectopic pregnancy. *Am J Obstet Gynecol.* 1987;156:669-674.
271. Wallach J. *Interpretation of Diagnostic Tests.* 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2000:761-763.
272. Wild D, ed. *The Immunoassay Handbook.* 2nd ed. London: Nature Publishing Group, 2001:418.

273. Primus FJ, Kelley EA, Hansen HJ, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. *Clin Chem* 1988;34(2):261-264.
274. Frantz AG, Kleinberg DL, Noel GL. Studies on Prolactin in Man. *Recent Prog. Horm Res.* 1972; 28:527-590.
275. Niall HD. The Chemistry of the Human Lactogenic Hormones. In: Boyns AR, Griffiths K, editors *Prolactin and Carcinogenesis: Proceedings of the Fourth Tenovus Workshop; March 1972; Cardiff, Wales.* Cardiff: Alpha Omega Alpha, 1972: 13-20.
276. Talwalker PK, Ratner A, Meites J. In Vitro Inhibition of Pituitary Prolactin Synthesis and Release by Hypothalamic Extract. *Am. J. Physiol* 1963; 205:213-218.
277. Bowers CY, Friesen HG, Hwang P, Guyda HJ, Folkers K. Prolactin and Thyrotropin Release in Man by Synthetic Pyroglutamylhistidylprolinamide. *Biochem-Biophys Res Commun* 1971;45:1033-1041.
278. Friesen H, Guyda H, Hwang P, Tyson JE, Barbeau A. Functional Evaluation of Prolactin Secretion: A Guide to Therapy. *J Clin Invest* 1972; 51:706-709.
279. Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin Directly Inhibits Basal as Well as Gonadotropin-Stimulated Secretion of Progesterone and 17 β -Estradiol in the Human Ovary. *J Clin Endocrinol Metab* 1982; 54:1246-1250
280. Kauppila A, Leinonen P, Vihko R, Ylostalo P. Metoclopramide-Induced Hyperprolactinemia Impairs Ovarian Follicle Maturation and Corpus Luteum Function in Women. *J Clin Endocrinol Metab* 1982; 54:955-960.
281. Andersen AN, Schioler V, Hertz J, Bennet P. Effect of Metoclopramide-Induced Hyperprolactinaemia on the Gonadotrophic Response to Oestradiol and LRH. *Acta Endocrinol* 1982; 100:1-9.
282. Franks S, Nabarro JDN, Jacobs HS. Prevalence and Presentation of Hyperprolactinaemia in Patients with "Functionless" Pituitary Tumours. *Lancet* 1977; i:778-780.
283. Frantz AG. Prolactin. *N Engl J Med* 1978; 298:201-207.
284. Vrontakis M, Friesen HG. Prolactin-Secreting Pituitary Tumors as a Cause of Impotence and Infertility in Men. *Internal Medicine for the Specialist* 1984; 5:180-194.
285. US Department of Health and Human Services. *Biosafety in Microbiological and Biomedical Laboratories.* 5th ed. Washington, DC: US Government Printing Office; December 2009.
286. Suh HK, Frantz, AG. Size Heterogeneity of Human Prolactin in Plasma and Pituitary Extracts. *J Clin Endocrinol Metab* 1974; 39:928-935.
287. Allolio B, Hoepfener A, Leonhardt U, Deuss U, Winkelmann W. Size Heterogeneity of Immunoreactive Prolactin in Patients with Prolactinoma. *Acta Endocrinologica* 1987; 114:475-482.
288. Fang VS, Refetoff S. Heterogeneous Human Prolactin from a Giant Pituitary Tumor in a Patient with Panhypopituitarism. *J Clin Endocrinol Metab* 1978; 47:780-787.

289. Cavaco B, Leite V, Santos MA, Sobrinho LG. Anti-prolactin (PRL) Autoantibodies Cause Asymptomatic Hyperprolactinemia: Bioassay and Clearance Studies of PRL-immunoglobulin G Complex. *J Clin Endocrinol Metab* 1995; 80:2342-2346.
290. Bonhoff A, Vuille JC, Gomez F, Gellersen B. Identification of Macroprolactin in a Patient with Asymptomatic Hyperprolactinemia as a Stable PRL-IgG Complex. *Exp Clin Endocrinol* 1995; 103:252-255.
291. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. *J Clin Chem Clin Biochem* 1983;21(11):709-720.
292. McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. *Urology* 1995;45:729-744.
293. Graves HCB. Nonprostatic sources of prostate-specific antigen: a steroid hormone-dependent phenomenon? *Clin Chem* 1995;41:7-9.
294. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostatespecific antigen in serum by a sensitive enzyme immunoassay. *Cancer Res* 1980;40:4658-4662.
295. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. *J Urol* 1991;145:907-923.
296. Kantoff PW, Talcott JA. The prostate specific antigen. Its use as a tumor marker for prostate cancer. *Hematol Oncol Clin N Amer* 1994;8:555-572.
297. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994 *J Urol* 1994;152:1358-1368.
298. Bunting S. A Guide to the Interpretation of Serum Prostate Specific Antigen Levels. *Clin Biochem* 1995;28:221-241.
299. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. *Eur J Biochem* 1990;194:755-763.
300. Stenman U-H, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. *Cancer Res* 1991;51:222-226.
301. Parker SL, Tong T, Bolden S, et al. Cancer Statistics, 1997. *CA Cancer J Clin* 1997;47:5-27.
302. Gerber GS, Chodak GW. Routine screening for cancer of the prostate (Review). *J Natl Ca Inst* 1991;83:329-335.
303. Lee F, Littrup PJ, Torp-Pedersen ST, et al. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. *Radiology* 1988;168:389-394.
304. Cooner WH, Mosely BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J Urol* 1990;143:1146-1154.

305. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol* 1994;151:1283-1290.
306. Crawford ED, DeAntoni EP, Etzioni R, et al. Serum Prostate-Specific Antigen and Digital Rectum Examination for Early Detection of Prostate Cancer in a National Community-Based Program. *Urology* 1996;47:863-869.
307. American Urological Association - Early Detection of Prostate Cancer Policy Statement. Board of Directors Minutes 1992.
308. Mettlin C, Jones G, Averette H, et al. Defining and Updating the American Cancer Society Guidelines for the Cancer-Related Checkup: Prostate and Endometrial Cancers. *CA-A Cancer Journal for Clinicians* 1993;43:42-46.
309. Walther PJ. Prostate Cancer Screening. Why the Controversy? *Surg Oncol Clin NA* 1995;4:315-334.
310. Jacobson JO. Can Screening for Early-Stage Prostate Cancer be Rationalized? *Hematol Oncol Clinics NA* 1996;10:549-564.
311. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. *Urology* 1996;48(suppl 6A):33-39.
312. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. *Urology* 1996;48(suppl 6A):81-86.
313. Chan DW, Bruzek DJ, Oesterling JE, et al. Prostate specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. *Clin Chem* 1987;33:1916-1920.
314. Hortin GL, Bahnson RR, Daft M, et al. Differences in values obtained with 2 assays of prostate specific antigen. *J Urol* 1988;139:762-765.
315. Morgan WR, Zincke H, Rainwater LM, et al. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). *J Urol* 1991;145:319-323.
316. Chybowski FM, Bergstralh EJ, Oesterling JE. The Effect of Digital Rectal Examination on the Serum Prostate Specific Antigen Levels. *J Urol* 1992;148:83-86.
317. Yuan JJJ, Coplen DE, Petros JA, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. *J Urol* 1992;147:810-814.
318. Tchetgen M-B, Song JT, Strawderman M, et al. Ejaculation increases the serum prostate-specific antigen concentration. *Urology* 1996;47:511-516.
319. Stenman U-H, Leinonen J, Zhang W-M. Problems in the determination of prostate specific antigen. *Eur J Clin Chem Biochem* 1996;34:735-740.
320. Watt KWK, Lee P-J, M'Timkulu T, et al. Human prostate-specific antigen: structural and functional similarity with serine proteases. *Proc Natl Acad Sci USA* 1986;83:3166-3170.

321. Belanger A, van Halbeek H, Graves HCB, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. *Prostate* 1995;27:187-197.
322. Gold P, Freedman SO. Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. *J Exp Med* 1964;121:439.
323. Krupey J, Gold P, Freedman SO. Physicochemical Studies of the Carcinoembryonic Antigens of the Human Digestive System. *J Exp Med* 1968;183:387.
324. Krupey J, Wilson T, Feedman SO, et al. The Preparation of Purified Carcinoembryonic Antigen of the Human Digestive System from Large Quantities of Tumor Tissue. *Immunochem* 1972;9(6):617-622.
325. Thomson DMP, Krupey J, Freedman SO, et al. The Radioimmunoassay of Circulating Carcinoembryonic Antigen of the Human Digestive System. *Proc Natl Acad Sci USA* 1969;64:161-167.
326. Zamcheck N. Carcinoembryonic Antigen: Quantitative Variations in Circulating Levels in Benign and Malignant Digestive Tract Diseases. *Adv Intern Med* 1974;19:413.
327. Go VLM, Ammon HV, Holtermuller KH, et al. Quantification of Carcinoembryonic Antigen-Like Activities in Normal Human Gastrointestinal Secretions. *Cancer* 1975;36:2346-2350.
328. Khoo SK, Warner NL, Lie JT, et al. Carcinoembryonic Antigenic Activity of Tissue Extracts: A Quantitative Study of Malignant and Benign Neoplasms. Cirrhotic Liver, Normal Adult and Fetal Organs. *Int J Cancer* 1973;11(3):681-687.
329. Hansen HJ, Lance KP, Krupey J. Demonstration of an Ion Sensitive Antigenic Site on Carcinoembryonic Antigen Using Zirconyl Phosphate Gel. *Clin Res* 1971;19:143.
330. Oehr P, Schlosser T, Adolphs HD. Applicability of an Enzymatic Test for the Determination of CEA in Serum and CEA-Like Products in Urine of Patients with Bladder Cancer. *Tumor Diagn* 1980;1:40.
331. Ng WW, Tong KJ, Tam TN, et al. Clinical Values of CA 19-9, CA125, and CEA in Malignant Obstructive Jaundice. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1995;55(6):438-446.
332. Jerzersek B, Cervek J, Rudolf Z, et al. Clinical Evaluation of Potential Usefulness of CEA, CA 15-3, and MCA in Follow-up Breast Cancer Patients. *Cancer Letters* 1996;110(1-2):137-144
333. Wollenberg B, Jan V, Schmit UM, et al. CYFRA 21-1 is not Superior to SCC Antigen and CEA in Head and Neck Squamous Cell Cancer. *Anticancer Res* 1996;16(5b):3117-3124.
334. Cerwenka H, Aigner R, Quehenberger F, et al. Preoperative Differential Diagnosis of Benign and Malignant Pancreatic Lesions - The Value of Pancreatic Secretory Trypsin Inhibitor, Procarboxypeptidase B, CA 19-9 and CEA. *Hepato-Gastroenterology* 1997;44(16):1117-1121.
335. Pastor A, Menendez R, Cremades JM, et al. Diagnostic Value of SCC, CEA and CYFRA 21.1 in Lung Cancer: A Bayesian Analysis. *Eur Respir J* 1997;10(3):603-609.

336. Maestranzi S, Przemioslo R, Mitchell H, et al. The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA 19-9 and CEA. *Ann Clin Biochem* 1998;35:99-103.
337. Duk JM, Aalders JG, Fluere GJ, et al. Tumor Markers CA 125, Squamous Cell Carcinoma Antigen, and Carcinoembryonic Antigen in Patients with Adenocarcinoma of the Uterine Cervix. *Obstet Gynecol* 1989;73(4):661-668.
338. Munck-Wikland E, Kuylensstierna R, Lindholm T, et al. Carcinoembryonic Antigen, CA 19-9, and CA 50 in Monitoring Human Squamous Cell Carcinoma of the Esophagus. *Anticancer Res* 1990;10(3):703-708.
339. Jager W, Kramer S, Palapelas V, et al. Breast Cancer and Clinical Utility of CA 15-3 and CEA. *Scand J Clin Lab Invest Suppl* 1995;221:87-92.
340. Ebert W, Hoppe M, Muley T, et al. Monitoring of Therapy in Inoperable Lung Cancer Patients by Measurement of CYFRA 21-1, TPA-M, TPS, CEA, and NSE. *Anticancer Res* 1997;17(4B): 2875-2878.
341. King J, Caplehorn JRM, Ross WB, et al. High Serum Carcinoembryonic Antigen Concentrations in Patients with Colorectal Liver Metastases is Associated with Poor Cell-Mediated Immunity, Which is Predictive of Survival. *Br J Surg* 1997;84:1382-1385.
342. Noda M, Kusunoki M, Yanagi H, et al. Serum Carcinoembryonic Antigen (CEA) Correlates with the Survival Time During 5-FU Hepatic Arterial Infusion Chemotherapy for Unresectable Colorectal Hepatic Metastase - Clinical Study. *International Journal of Oncology* 1996;9(4):741-746.
343. Korenaga D, Saeki H, Mawatari K, et al. Serum Carcinoembryonic Antigen Concentration Doubling Time Correlates with Tumor Biology and Life Expectancy in Patients with Recurrent Gastrointestinal Carcinoma. *Archives of Surgery* 1997;132(2):188-194.
344. Nakayama T, Watanabe M, Teramoto T, et al. Slope Analysis of CA 19-9 and CEA for Predicting Recurrence in Colorectal Cancer Patients. *Anticancer Res* 1997;17(2b):1379-1382.
345. Lokich JJ, Zamcheck N, Lowenstein M. Sequential Carcinoembryonic Antigen Levels in the Therapy of Metastatic Breast Cancer. *Ann Intern Med* 1978;39:902.
346. Yasue M, Sakamoto J, Teramukai S, et al. Prognostic Values of Preoperative and Postoperative CEA and CA 19-9 Levels in Pancreatic Cancer. *Pancreas* 1994;9(6):735-740.
347. Zamcheck N, Martin EW. Factors Controlling the Circulating CEA Levels in Pancreatic Cancer. Some Clinical Correlations. *Cancer* 1981;47:1620.
348. Alsabti EAK, Kamel A. Carcinoembryonic Antigen (CEA) in Patients with Malignant and Non-Malignant Disease. *Neoplasma* 1979;26:603.
349. Khoo SK, Whitaker S, Jones I, et al. Predictive Value of Serial Carcinoembryonic Antigen Levels in Long-Term Follow-Up of Ovarian Cancer. *Cancer* 1979;43:2471.
350. Chevinsky AH. CEA in Tumors of Other than Colorectal Origin. *Semin Surg Oncol* 1991;7(3):162-166.

351. Diez M, Gomez A, Hernando F, et al. Serum CEA, CA125, and SCC Antigens and Tumor Recurrence in Resectable Non-Small Cell Lung Cancer. *Int J Biol Markers* 1995;10(1):5-10.
352. Bast RC, Bates S, Bredt AB, et al. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer. *J Clin Oncol* 1996;14(10):2843-2877.
353. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator in Colorectal Cancer. *N Engl J Med* 1978;299(9):448-451.
354. Concannon JP, Dalbow MH, Hodgson SE, et al. Prognostic Value of Preoperative Carcinoembryonic Antigen (CEA) Plasma Levels in Patients with Bronchogenic Carcinoma. *Cancer* 1978;42:1477-1483.
355. Ikeda Y, Mori M, Kajiyama K, et al. Indicative Value of Carcinoembryonic Antigen (CEA) for Liver Recurrence Following Curative Resection of Stage II and III Gastric Cancer. *Hepatogastroenterol* 1996;43(11):1281-1287.
356. Gebauer G, Muller-Ruchholtz W. Tumor Marker Concentrations in Normal and Malignant Tissues of Colorectal Cancer Patients and Their Prognostic Relevance. *Anticancer Res* 1997;17(4a):2731-2734.
357. Hotakainen K, Tanner P, Alfthan H, et al. Comparison of three immunoassays for CA 19-9. *Clin Chim Acta.* 2009;400:123-127.
358. Passerin R, Cassatella M, Boveri S, et al. Routine Testing and Comparison of Two Automated Immunoassays in a Reference Oncology Center. *Am J Clin Pathol.* 2012;138:281-287.
359. Uhlenbruck G, Holler U, Heising J, et al. Sialylated Lea Blood Group Substances Detected by the Monoclonal Antibody CA 19-9 in Human Seminal Plasma and Other Organs. *Urol Res (Germany, West)* 1985;13(15):223-226.
360. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal Carcinoma-Specific Antigen: Detection by Means of Monoclonal Antibodies. *Proc Natl Acad Sci USA* 1979;76:1438-1442.
361. Magnani JL, Brockhaus M, Smith DF, et al. A Monosialoganglioside is a Monoclonal Antibody-Defined Antigen of Colon Carcinoma. *Science* 1981;212:55-56.
362. Magnani J, Nilsson B, Brockhaus M, et al. The Antigen of a Tumor-Specific Monoclonal Antibody is a Ganglioside Containing Sialylated Lacto-N-Fucopentaose II. *Fed Proc* 1982;41:898.
363. Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the Gastrointestinal and Pancreatic Cancer-Associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin. *Cancer Res* 1983;43:5489-5492.
364. Del Villano BC, Brennan S, Brock P, et al. Radioimmunoassay for a Monoclonal Antibody-Defined Tumor Marker, CA 19-9. *Clin Chem* 1983;29:549-552.
365. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen Assays in Detecting Cancer of the Pancreas. *Gastroent* 1986;90:343-349.
366. Ritts RE Jr, Del Villano BC, Go VLW, et al. Initial Clinical Evaluation of an Immunoradiometric Assay for CA 19-9 Using the NCI Serum Bank. *Int J Cancer* 1984;33:339-345.

367. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a New Tumour Marker, CA 19-9, with Alpha-Fetoprotein and Carcinoembryonic Antigen in Patients with Upper Gastrointestinal Diseases. *J Clin Pathol* 1984;37:218–222.
368. Gupta MK, Arciaga R, Bocci L, et al. Measurement of a Monoclonal-Antibody-Defined Antigen (CA 19-9) in the Sera of Patients with Malignant and Nonmalignant Diseases. Comparison with Carcinoembryonic Antigen. *Cancer* 1985;56(2):277–283.
369. Andriulli A, Gindro T, Piantino P, et al. Prospective Evaluation of the Diagnostic Efficacy of CA 19-9 Assay as a Marker for Gastrointestinal Cancers. *Digestion* 1986;33(1):26–33.
370. Patai A, Heber S, Dobronte Z, et al. Diagnostic Values of CA 19-9 and CEA in Gastrointestinal Diseases. *Orv Hetil* 1992;133(21):1301–1304,1307.
371. Ritts RE and Pitt HA. CA 19-9 in Pancreatic Cancer. *Surgical Oncology Clinics of North America* 1998;7:93-101.
372. Duffy MJ, van Dalen A, Haglund C. et al. Clinical Utility of Biochemical Markers in Colorectal Cancer: European Group on Tumour Markers (EGTM) Guidelines. *Eur J Cancer* 2003;39:718-727.
373. Von Ritter C, Eder MI, Stieber P, et al. Biliary Mucin Secreted by Cultured Human Gallbladder Epithelial Cells Carries the Epitope of CA 19-9. *Anticancer Res* 1997;17(4B):2931–2934.
374. Adachi Y, Iso Y, Moriyama M, et al. Increased Serum CA 19-9 in Patients with Xanthogranulomatous Cholecystitis. *Hepta- Gastroenterology* 1998;45:77–80.
375. Duffy MJ, O’Sullivan F, McDonnell TJ, et al. Increased Concentrations of the Antigen CA 19-9 in Serum of Cystic Fibrosis Patients. *Clin Chem* 1985;31:1245–1246 (Letter).
376. Kane RE, Penny J, Walker K, et al. Changes in the CA 19-9 Antigen and Lewis Blood Group with Pulmonary Disease Severity in Cystic Fibrosis. *Pediatr Pulmonol* 1992;12(4):221–226.
377. Wu JT and Chang J. Chromatographic Characterization of CA 19-9 Molecules from Cystic Fibrosis and Pancreatic Carcinoma. *J Clin Lab Anal* 1992;6(4):209–215.
378. Wu JT, Olsen J, Walker K, Tumor Markers CA 19-9 and CA 195 Are Also Useful as Markers for Cystic Fibrosis. *J Clin Lab Anal* 1992;5(3):151-161.
379. Staab HJ, Brummendorf T, Hornung A, et al. The Clinical Validity of Circulating Tumor-Associated Antigens CEA and CA 19-9 in Primary Diagnosis and Follow-up of Patients with Gastrointestinal Malignancies. *Klin Wochenschr* 1985;63(3):106–115.
380. Ychou M, Tuszinski T, Pignon J-P, et al. Gastric Carcinoma: Comparison between CEA and CA 19-9 for diagnosis of recurrence after gastrectomy. *Gastroenterol Clin Biol* 1992;16(11):848–852.
381. Grem J. The Prognostic Importance of Tumor Markers in Adenocarcinomas of the Gastrointestinal Tract. *Curr Opin Oncol* 1997;9(4):380–387.
382. Gartner U, Scheulen ME, Conradt C, et al. Value of Tumour-Associated Antigen CA 72-4 Compared with CEA and CA 19-9 in the Followup of Patients Operated for Gastric Carcinoma. *Dtsch med Wschr* 1998;123:69–73.
383. Willet CG, Daly WJ, Warshaw AL, CA 19-9 is an Index of Response to Neoadjuvantive Chemoradiation Therapy in Pancreatic Cancer. *Am J Surg* 1996;172(4):350–352.

384. Filella X, Molina R, Grau JJ, et al. Prognostic Value of CA 19.9 Levels in Colorectal Cancer. *Ann Surg* 1992;216(1):55–59.
385. Kouri M, Pyrhonen S, Kuusela P, Elevated CA 19-9 as the Most Significant Prognostic Factor in Advanced Colorectal Carcinoma. *J Surg Oncol* 1992;49(2):78–85.
386. Reiter W, Stieber P, Reuter C, et al. Preoperative Serum Levels of CEA and CA 19-9 and Their Prognostic Significance in Colorectal Carcinoma. *Anticancer Res* 1997;17(4B):2935–2938.
387. Gogas H, Lofts FJ, Evans TRJ, et al. Are Serial Measurements of CA 19-9 Useful in Predicting Response to Chemotherapy in Patients with Inoperable Adenocarcinoma of the Pancreas? *Br J Cancer* 1998;77:325-328.
388. Safi F, Schlosser W, Falkenreck S, et al. Prognostic Value of CA 19-9 Serum Course in Pancreatic Cancer. *Hepato-Gastroenterol* 1998;45:253-259.
389. Tempero MA, Uchida E, Takasaki H, et al. Relationship of Carbohydrate Antigen 19-9 and Lewis Antigens in Pancreatic Cancer. *Cancer Res* 1987;47:5501–5503.
390. Tietz NW. *Tietz Textbook of Clinical Chemistry*. 3rd Edition. Philadelphia, PA: B. Saunders Company, 1999;330.
391. National Committee for Clinical Laboratory Standards. Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guideline-Second Edition. NCCLS Document EP6-P2. Wayne, PA: NCCLS, 2001.
392. Bast RC Jr., Feeney M, Lazarus H, et al. Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma. *J Clin Invest* 1981;68:1331-1337.
393. Kabawat SE, Bast RC, Welch WR, et al. Immunopathologic Characterization of a Monoclonal Antibody that Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types. *Am J Clin Pathol* 1983;79:98-104.
394. Kabawat SE, Bast RC Jr., Bhan AK, et al. Tissue Distribution of a Coelomic-Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125. *Int J Gynecol Pathol* 1983;2:275-285.
395. O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. *Tumor Biol* 2001;22:348-366.
396. NIH Consensus Conference, Ovarian Cancer: Screening, Treatment, and Follow-up. *JAMA* 1995;273:491-497.
397. Kenemans P, Yedema CA, Bon GG, et al. CA 125 in Gynecological Pathology-A Review. *Eur J Obstet Gynecol and Reprod Biol* 1993;49:115-124
398. Bast RC Jr., Klug TL, St. John E, et al. A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer. *N Engl J Med* 1983;309:883-887.
399. Bast RC Jr., Klug TL, Schaetzel E, et al. Monitoring Human Ovarian Carcinoma with a Combination of CA 125, CA 19-9, and Carcinoembryonic Antigen. *Am J Obstet Gynecol* 1984;149:553-559.
400. Niloff JM, Bast RC Jr., Schaetzel EM, et al. Predictive Value of CA 125 Antigen Levels in Second-Look Procedures for Ovarian Cancer. *Am J Obstet Gynecol* 1985;151:981-986.
401. Niloff JM, Knapp RC, Schaetzel E, et al. CA 125 Antigen Levels in Obstetric and Gynecologic Patients. *Obstet Gynecol* 1984;64:703-707.

402. Atack DB, Nisker JA, Allen HH, et al. CA 125 Surveillance and Second-look Laparotomy in Ovarian Carcinoma. *Am J Obstet Gynecol* 1986;154:287-289.
403. Schilthuis MS, Aalders JG, Bouma J, et al. Serum CA 125 Levels in Epithelial Ovarian Cancer: Relation with Findings at Second-Look Operations and Their Role in the Detection of Tumour Recurrence. *Br J Obstet Gynaecol* 1987;94:202-207.
404. Berek JS, Knapp RC, Malkasian GD, et al. CA 125 Serum Levels Correlated with Second-Look Operations Among Ovarian Cancer Patients. *Obstet Gynecol* 1986;67:685-689.
405. Crombach G, Zippel HH, Wurz H. Clinical Significance of Cancer Antigen 125 (CA 125) in Ovarian Cancer. *Cancer Detect Prev* 1985;8:135-139.
406. Shih I, Sokoll LJ, Chan DW. Ovarian Cancer. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW and Schwartz MK, editors. *Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications*. Washington, DC: AACCC Press 2002:239-252
407. Bergmann JF, Beaugrand M, Labadie H, et al. CA 125 (Ovarian Tumour-Associated Antigen) in Ascitic Liver Diseases. *Clin Chim Acta* 1986;155:163-166.
408. Molina R, Ballesta AM, Casals E, et al. Value of CA 12.5 Antigen as Tumour Marker: Preliminary Results. In: Peeters H, ed. *Protides of the Biological Fluids: Proceedings of the Thirty-second Colloquium, 1984*. Oxford, U.K.: Pergamon Press; 1984;613-616.
409. Ruibal A, Encabo G, Miralles EM, et al. CA 125 Seric Levels in Non Ovarian Pathologies. In: Peeters H, ed. *Protides of the Biological Fluids: Proceedings of the Thirty-second Colloquium, 1984*. Oxford, U.K.: Pergamon Press; 1984;605-608.
410. Barbieri RL, Niloff JM, Bast RC Jr., et al. Elevated Serum Concentrations of CA-125 in Patients with Advanced Endometriosis. *Fertil Steril* 1986;45:630-634.
411. Pittaway DE. CA-125 in Women with Endometriosis. *Obstet Gynecol Clin North Am* 1989;16(1):237-252.
412. Takahashi K, Kijima S, Yoshino K, et al. Serum CA 125 as a Marker for Patients with External Endometriosis. *Int J Fertil* 1989;34(2):143-148.
413. Giudice LC, Jacobs A, Pineda J, et al. Serum Levels of CA-125 in Patients with Endometriosis: A Preliminary Report. *Fertil Steril* 1986;45(6):876-878.
414. Masahashi T, Matsuzawa K, Ohsawa M, et al. Serum CA 125 Levels in Patients with Endometriosis: Changes in CA 125 Levels During Menstruation. *Obstet Gynecol* 1988;72(3):328-331.
415. Malkasian GD Jr, Podratz KC, Stanhope CR et al. CA 125 in Gynecologic Practice. *Am J Obstet Gynecol* 1986;155:515-518.
416. Halila H, Stenman UH, Seppala M. Ovarian Cancer Antigen CA 125 Levels in Pelvic Inflammatory Disease and Pregnancy. *Cancer* 1986;57:1327-1329.
417. Haga Y, Sakamoto K, Egami H, et al. Evaluation of Serum CA125 Values in Healthy Individuals and Pregnant Women. *Am J Med Sci* 1986;292(1):25-29.
418. Takahashi K, Yamane Y, Yoshino K, et al. Studies on Serum CA125 Levels in Pregnant Women. *Acta Obst Gynaec Jpn* 1985;37(9): 1931-1934.
419. Pittaway DE, Fayez JA, Douglas JW. Serum CA-125 in the Evaluation of Benign Adnexal Cysts. *Am J Obstet Gynecol* 1987;157:1426-1428.

420. Pittaway DE, Fayez JA. Serum CA-125 Antigen Levels Increase During Menses. *Am J Obstet Gynecol* 1987;156:75-76.
421. Niloff JM, Klug TL, Schaetzl E, et al. Elevation of Serum CA125 in Carcinomas of the Fallopian Tube, Endometrium, and Endocervix. *Am J Obstet Gynecol* 1984;148:1057-1058.
422. Haga Y, Sakamoto K, Egami H, et al. Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive System. *Am J Med Sci* 1986;292(1):30-34.
423. Duk JM, Aalders JG, Fleuren GJ, et al. CA 125: A Useful Marker in Endometrial Carcinoma. *Am J Obstet Gynecol* 1986;155:1097-1102.
424. Kinders RJ, Hass GM. Interference in Immunoassays by Human Anti-Mouse Antibodies. *Eur J Cancer* 1990;26:647-648.
425. Muto MG, Finkler NJ, Kassis AI, et al. Human Anti-Murine Antibody Responses in Ovarian Cancer Patients Undergoing Radioimmunotherapy with Murine Monoclonal Antibody OC-125. *Gynecol Oncol* 1990;38:244-248.
426. Budavari S, editor. *Merck Index (11th Ed.)*. Rahway, NJ: Merck and Co., Inc., 1989:868.
427. Ekins RP, editor. *Methods for the Measurement of Free Thyroid Hormones*. Amsterdam: Excerpta Medica Foundation. 1979;72-92.
428. Robbins J, Rall JE. The Iodine-Containing Hormones. In: *Hormones in Blood (3rd Ed.)*. London: Academic Press, 1979:1:632-667.
429. Hamburger JL. Evolution of Toxicity in Solitary Nontoxic Autonomously Functioning Thyroid Nodules. *J Clin Endocrinol Metab* 1980;50: 1089-1093.
430. PW. Diagnosis of Thyrotoxicosis. In: Braverman LE, Utiger RD, editors. *The Thyroid (6th Ed.)*. Philadelphia: JB Lippincott Co., 1991:880-886.
431. Wahner HW. T3 Hyperthyroidism. *Mayo Clin Proc* 1972;47:938-943.
432. Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral Tissue Mechanism for Maintenance of Serum Triiodothyronine Values in a Thyroxine-Deficient State in Man. *J Clin Invest* 1984;73:570-575.
433. Lee LA, Mooney RA, Woolf PD. Clinical Utility of Measuring Free Thyroxin and Free Triiodothyronine in Serum of Critically Ill Patients by Ultrafiltration. *Clin Chem* 1986; 32:797-800.
434. Wilke TJ, Eastment HT. Discriminative Ability of Tests for Free and Total Thyroid Hormones in Diagnosing Thyroid Disease. *Clin Chem* 1986; 32:1746:50.
435. Kaptein EM, Grieb DA, Spencer CA, et al. Thyroxine Metabolism in the Low Thyroxine State of Critical Nonthyroidal Illnesses. *J Clin Endocrinol Metab* 1981; 53:764-771.
436. Merimee TJ, Fineberg ES. Starvation-Induced Alterations of Circulating Thyroid Hormone Concentrations in Man. *Metabolism* 1976; 25:79-83.
437. Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition*. CLSI Document EP17-A2. Wayne, PA: CLSI; 2012.
438. Lerman J. The Physiologic Activity of L-Triiodothyronine. *J Clin Endocrinol Metab* 1953;13:1341-1346.

439. Robbins J, Rall JE. Thyroxine-Binding Proteins. In: Gray CH, Bacharach AL, editors. *Hormones in Blood* (2nd Ed.). London: Academic Press, 1967;1:427-440.
440. Sterling K, Refetoff S, Selenkow HA. T3 Thyrotoxicosis: Thyrotoxicosis Due to Elevated Serum Triiodothyronine Levels. *JAMA* 1970;213: 571-575.
441. Witherspoon LR, Shuler SE. Estimation of Free Thyroxine Concentration: Clinical Methods and Pitfalls. *J Clin Immunoassay*. 1984;7:192-205.
442. Bermudez F, Surks MI, Oppenheimer JH. High Incidence of Decreased Serum Triiodothyronine Concentration in Patients with Nonthyroid Disease. *J Clin Endocrinol Metab*. 1975;41:27-40.
443. Larsen PR. Triiodothyronine: Review of Recent Studies of Its Physiology and Pathophysiology in Man. *Metabolism* 1972;21:1073-1092.
444. Abuid J, Klein AH, Foley Jr TP, Larsen TP. Total and Free Triiodothyronine and Thyroxine in Early Infancy. *J Clin Endocrinol Metab* 1974;39: 263-268.
445. Szpunar WE, Stoffer SS, Bednarz MN. Clinical Evaluation of a Thyroxine-Binding Globulin Assay in Calculating a Free-Thyroxine Index. *J Nucl Med* 1981;22:793-795.
446. Nusynowitz L. Free Thyroxine Index. *JAMA* 1975;232:1050.
447. Oppenheimer JH. Role of Plasma Proteins in the Binding, Distribution and Metabolism of the Thyroid Hormones. *N Engl J Med* 1968; 278:1153-1162.
448. Woeber KA, Ingbar SH. The Contribution of Thyroxine-Binding Prealbumin to the Binding of Thyroxine in Human Serum, as Assessed by Immunoabsorption. *J Clin Invest* 1968;47:1710-172
449. Tabachnick M, Giorgio NA Jr. Thyroxine – Protein Interactions *Arch Biochem Biophys* 1964;105:563-569.
450. Stockigt JR, Topliss DJ, Barlow JW, White EL, Hurley DM, Taft P. Familial Euthyroid Thyroxine Excess: An Appropriate Response to Abnormal Thyroxine Binding Associated with Albumin. *J Clin Endocrinol Metab* 1981;53:353-359.
451. Ruiz M, Rajatanavin R, Young RA, Taylor C, Brown R, Braverman LE, et al. Familial Dysalbuminemic Hyperthyroxinemia. *N Engl J Med* 1982;306:635-639.
452. Hennemann G, Docter R, Krenning EP, Bos G, Otten M, Visser TJ. Raised Total Thyroxine and Free Thyroxine Index but Normal Free Thyroxine. *Lancet* 1979;1:639-642.
453. Stockigt JR, Lim CF, Barlow JW, Stevens V, Topliss DJ, Wynne KN. High Concentrations of Furosemide Inhibit Serum Binding of Thyroxine. *J Clin Endocrinol Metab* 1984;59:62-66
454. Stockigt JR, Lim CF, Barlow JW, Stevens V, Wynne KN, Mohr VS, Topliss DJ, et al. Interaction of Furosemide with Serum Thyroxine-Binding Sites: In Vivo and In Vitro Studies and Comparison with Other Inhibitors. *J Clin Endocrinol Metab* 1985;60:1025-1031.
455. Ratcliffe WA, Hazelton RA, Thomson JA, Ratcliffe JG. The Effect of Fenclofenac On Thyroid Function Tests In Vivo and In Vitro. *Clin Endocrinol* 1980;13:569-575.

456. Kurtz AB, Capper SJ, Clifford J, Humphrey MJ, Lukinac L. The Effect of Fenclofenac On Thyroid Function. *Clin Endocrinol* 1981;15:117-124.
457. Pearson DWM, Ratcliffe WA, Thomson JA, Ratcliffe JG. Biochemical and Clinical Effects of Fenclofenac In Thyrotoxicosis. *Clin Endocrinol* 1982;16:369-373.
458. Larsen PR, Dockalova J, Sipula D, Wu FM. Immunoassay of Thyroxine in Unextracted Human Serum. *J Clin Endocrinol Metab* 1973; 37:177-182.
459. Chopra IJ. A Radioimmunoassay for Measurement of Thyroxine in Unextracted Human Serum. *J Clin Endocrinol Metab* 1972; 34:938-947.
460. Refetoff S, Hayen SR, Selenkow HA. Estimation of the T4 Binding Capacity of Serum TBG and TBPA by a Single T4 Load Ion Exchange Resin Method. *J Nucl Med* 1972;13:2-12.
461. Clark F, Horn DB. Assessment of Thyroid function by the Combined Use of the Serum Protein-Bound Iodine and Resin Uptake of ¹³¹I-Triiodothyronine. *J Clin Endocrinol Metab* 1965;25:39-45.
462. Ellis SM, Ekins RP. The Radioimmunoassay of Serum Free Triiodothyronine and Thyroxine. In: Pasternak CA, editor. *Radioimmunoassay in Clinical Biochemistry*. London: Heyden, 1975;25:187-194.
463. Nelson JC, Tomei RT. Direct Determination of Free Thyroxine in Undiluted Serum by Equilibrium Dialysis/Radioimmunoassay in Serum. *Clin Chem* 1988;34:1737-1744.
464. Sophianopoulos J, Jerkunica I, Lee CN, Sgoutas D. An Improved Ultrafiltration Method for Free Thyroxine and Triiodothyronine in Serum. *Clin Chem* 1980;26:159-162.
465. Shannon N, Woolf PD. Determination of Free Thyroxine in serum by Ultrafiltration: Validation of a Method and Preliminary Results. *Clin Chem* 1984;30:1770-1773.
466. Bayer MF, McDougall IR. Radioimmunoassay of Free Thyroxine in Serum: Comparison with Clinical Findings and Results of Conventional Thyroid-Function Tests. *Clin Chem* 1980;26:1186-1192.
467. Sturgess ML, Weeks I, Evans PJ, Mpoko CN, Laing I, Woodhead JS. An Immunochemiluminometric Assay for Serum Free Thyroxine. *Clin Endocrinol* 1987;27:383-393.
468. Vermeulen A, Verdonck L, Kaufman J, et al. A critical evaluation of simple methods for the estimation of free testosterone in serum. *Journal of Endocrinology and Metabolism* 1999; 84:3666-3672.
469. Selby, C. Sex hormone binding globulin: origin, function and clinical significance. *Ann Clin Biochem*. 1990;27:532-541.
470. Pugeat M, Crave JC, Tourniare J, Forest MG. Clinical Utility of Sex Hormone Binding Globulin Measurement. *Horm Res*. 1996; 45 (3-5):148-155.
471. Braunstein GD. Androgen insufficiency in women: summary of critical issues. *Fertility and Sterility* 2002;77(4, suppl 4):S94-95.
472. Pierce JG. The Subunits of Pituitary Thyrotropin. Their Relationship to other Glycoprotein Hormones. *Endocrinology* 1971; 89:1331-1344.

473. Rees Smith B, Pyle GA, Petersen VB, Hall R. Interaction of Thyrotropin with the Human Thyrotropin Receptor. *J Endocrinol* 1977; 75:391-400.
474. Sterling K, Lazarus JH. The Thyroid and Its Control. *Annu Rev Physiol* 1977; 39:349-371.
475. Patel YC, Alford FP, Burger HG. The 24-Hour Plasma Thyrotropin Profile. *Clin Sci* 1972; 43:71-77.
476. Morley JE. Neuroendocrine Control of Thyrotropin Secretion. *Endocr Rev* 1981; 2:396-436.
477. Burger HG, Patel YC. The Value of Serum Thyrotropin Measurement in the Diagnosis and Management of Hypothyroidism. *Med J Aust* 1972; 2:293-297.
478. Petersen VB, McGregor AM, Belchetz PE, Elkeles RS, Hall R. The Secretion of Thyrotropin with Impaired Biological Activity in Patients with Hypothalamic-Pituitary Disease. *Clin Endocrinol* 1978; 8:397-402.
479. Faglia G, Bitensky L, Pinchera A, Ferrari C, Paracchi A, Beck-Pecoz P, et al. Thyrotropin Secretion in Patients with Central Hypothyroidism: Evidence for Reduced Biological Activity of Immunoreactive Thyrotropin. *J Clin Endocrinol Metab* 1979; 48:989-998
480. Beck-Pecoz P, Amr S, Menezes-Ferreira MM, Faglia G, Weintraub BD. Decreased Receptor Binding of Biologically Inactive Thyrotropin in Central Hypothyroidism. *N Engl J Med* 1985; 312:1085-1090.
481. Wehmann RE, Rubenstein HA, Pugeat MM, Nisula BC, Extended Clinical Utility of a Sensitive and Reliable Radioimmunoassay of Thyroid-Stimulating Hormone. *South Med J* 1983; 76:969-976.
482. Lauridsen UB, Deckert T, Friis TH, Kirkegaard C, Hansen JM, Siersbaek-Nielsen K. Estimation of Serum Thyrotropin (TSH) and Stimulation with Thyrotropin-Releasing Hormone (TRH) in Thyroid Diseases. *Acta Med Scand* 1974; 196:171-176.
483. Jackson IMD. Thyrotropin-Releasing Hormone. *N Engl J Med* 1982; 306:145-155.
484. Spencer CA. Clinical Uses and Limitations of Rapid TSH Assays. *Medical Laboratory Products* 1988; 17-19.
485. Bayer MF. Performance Criteria for Appropriate Characterization of “(Highly) Sensitive” Thyrotropin Assays. *Clin Chem* 1987; 33:630-631.
486. Hay ID, Bayer MF, Kaplan MM, Klee GG, Larsen PR, and Spencer CA. American Thyroid Association Assessment of Current Free Thyroid Hormone and Thyrotropin Measurements and Guidelines for Future Clinical Assays. *Clin Chem* 1991; 37:2002-2008.
487. Friedman RB, Young DS. *Effects of Disease on Clinical Laboratory Tests*, 2nd ed. Washington, DC: AACC Press, 1989.
488. Thomas L. Immunochemical technics. In: Thomas L, editor. *Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results*, 1st ed. Frankfurt/Main, Germany: TH-Books Verlagsgesellschaft; 1998:1427-41.
489. Simo JM, Joven J, Cliville X, et al. Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. *Clin Chem* 40;1994:625-9.

490. Westgard JO, Barry PL. Cost-effective Quality Control: Managing the Quality and Productivity of Analytical Processes. Washington, DC: AACC Press, 1986.
491. Young DS. Effects of Drugs on Clinical Laboratory Tests, 5th ed. Washington, DC: AACC Press, 2000.
492. Catt KJ, Pierce JG. Gonadotropic Hormones of the Adenohypophysis. In: Yen SSC and Jaffe RB editors. Reproductive Endocrinology. Philadelphia: Saunders, 1978:34-62.
493. Jeffcoate SL. The Control of Testicular Function in the Adult. Clinics in Endocrinology and Metabolism 1975;4:521-543.
494. Braunstein GD, Rasor J, Adler D, et al. Serum Human Chorionic Gonadotropin Levels Throughout Normal Pregnancy. Am J Obstet Gynecol 1976; 126:678-681.
495. Brody S, Carlstrom G. Immunoassay of Human Chorionic Gonadotropin in Normal and Pathologic Pregnancy. J Clin Endocrinol Metab 1962;22: 564-574.
496. Lab Report For Physicians. Standardization of Human Chorionic Gonadotropin. December 1985; 7:92-94.
497. Swaminathan N, Bahl OP. Dissociation and Recombination of the Subunits of Human Chorionic Gonadotropin. Biochem Biophys Res Commun 1970; 40:422-427.
498. Human Reproduction Unit, World Health Organization, Geneva, Switzerland. Assay of Protein Hormones Related to Human Reproduction: Problems of Specificity of Assay Methods and Reference Standards. Acta Endocrinol 1972; 71:625-637.
499. Saxena BB, Landesman R. Diagnosis and Management of Pregnancy by the Radioreceptor Assay of Human Chorionic Gonadotropin. Am J Obstet Gynecol 1978; 131:97-107.
500. Manganiello PD, Nazian SJ, Ellegood JO, et al. Serum Progesterone, 17 α -Hydroxyprogesterone, Human Chorionic Gonadotropin, and Prolactin in Early Pregnancy and a Case of Spontaneous Abortion. Fertil Steril 1981; 36:55-60.
501. Kadar N, DeVore G, Romero R. Discriminatory hCG Zone: Its Use in the Sonographic Evaluation for Ectopic Pregnancy. Obstet Gynecol 1981; 58:156-161.
502. Cole L A. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol, 1998;71:325-329.
503. Husa RO. The Clinical Marker hCG, Westport CT: Praeger Publishers. 1987: 77-95, 137-150.
504. Husa RO, Rinke ML, Schweitzer PG. Discordant human chorionic gonadotropin results: causes and solutions. Obstet Gynecol, 1985;65:211-219.
505. Mishalani SH, Seliktar J, Braunstein GD. Four Rapid Serum-Urine Combination Assays of Choriogonadotropin (hCG) Compared and Assessed for Their Utility in Quantitative Determinations of hCG. Clin Chem. 40/10, 1944-1949 (1994).
506. Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT. Ectopic Production of Human Chorionic Gonadotropin by Neoplasms. Ann Intern Med 1973; 78:39-45.

507. Husa RO. Clinical Utility of Human Chorionic Gonadotropin and α -Subunit Measurements. *Obstet Gynecol* 1982; 60:1-12.
508. Alftan H, Haglund C, Dabek J, et al. Concentrations of human choriogonadotropin, its β -subunit, and the core fragment of the β -subunit in serum and urine of men and nonpregnant women. *Clin Chem*, 1992; 38:1981-1987.
509. Borkowski A, Muquardt C. Human chorionic gonadotropin in the plasma of normal, nonpregnant subjects. *N Engl J Med*, 1979;301:298-302.
510. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. *N Engl J Med* 319:189-194, 1988.
511. Lenton EA, Neal LM, Sulaiman R. Plasma Concentrations of Human Chorionic Gonadotropin from the Time of Implantation until the Second Week of Pregnancy. *Fertil Steril* 1982; 37:773-778.
512. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J Clin Endocrinol Metab* 1981;53:58-68.
513. Ryan KJ. Placental Synthesis of Steroid Hormones. In: Tulchinsky D, Ryan KJ, editors. *Maternal-Fetal Endocrinology*. Philadelphia: WB Saunders Co. 1980:3-16.
514. Speroff L, Glass RH, Kase NG. Regulation of the Menstrual Cycle. In: *Clinical Gynecologic Endocrinology and Infertility*, 3rd ed. Baltimore: Williams and Wilkins. 1983:75-100.
515. Speroff L, Glass RH, and Kase NG. The Endocrinology of Pregnancy. In: Mitchell C, editor. *Clinical Gynecologic Endocrinology and Infertility*, 5th ed. Baltimore: Williams and Wilkins. 1994; 251-289.
516. Lauritzen C, Klopper A. Estrogens and Androgens, In: Fuchs F, Klopper A, editors. *Endocrinology of Pregnancy*. Philadelphia: Harper and Row, 1983:73-91.
517. Locarnini SA, Ferris AA, Lehmann NI, Gust ID. The antibody response following hepatitis A infection. *Intervirology* 1977;8:309-318.
518. Bradley DW, Maynard JE, Hindman SH, et al. Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. *J Clin Microbiol* 1977;5:521-530.
519. Bradley DW, Fields HA, McCaustland KA, et al. Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus. *J Clin Microbiol* 1979;9(1):120-127.
520. Deinhardt FW, Frosner GG, Scheidt R, Abb J. Significance of anti-HAV of the IgM class for the diagnosis of hepatitis A. In: Vyas GN, Cohen SN, Schmid R, eds. *Viral Hepatitis*. Philadelphia, PA: The Franklin Institute Press; 1978:736.
521. Decker RH, Kosakowski SM, Vanderbilt AS, et al. Diagnosis of acute hepatitis A by HAVAB-M, a direct radioimmunoassay for IgM anti-HAV. *Am J Clin Pathol* 1981;76:140-147.
522. Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and prevention. *Clin Chem* 1997;43:1494-1499.
523. Banatvala JE, Brown DW. Rubella. *Lancet* 2004;363(9415):1127-1137.

524. Preblub SR, Alford CA Jr. Rubella. In: Remington JS and Klein JO, editors. Infectious Diseases of the Fetus and Newborn infant (3rd ed.). Philadelphia: Saunders, 1990.
525. Dimech W, Panagiotopoulos L, Marler J, et al. Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies. Clin Diagn Lab Immunol 2005;12(9):1104-1108.
526. Hamkar R, Jalilvand S, Mohktari-Azad T, et al. Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine. J Virol Methods 2005;130(1-2):59-65.
527. Tipples GA, Hamkar R, Mohktari-Azad T, et al. Evaluation of rubella IgM enzyme immunoassays. J Clin Virol 2004;30(3):233-238.
528. Best JM, O'Shea S, Tipples G, et al. Interpretation of rubella serology in pregnancy—pitfalls and problems. BMJ 2002;325(7356):147-148.
529. Enders G, Knotek F. Detection of IgM antibodies against rubella virus: comparison of two indirect ELISAs and an anti-IgM capture immunoassay. J Med Virol 1986;19:377.
530. Долгов В. В., Меньшиков В. В. Клиническая лабораторная диагностика. Национальное руководство //М.: ГЭОТАР-Медиа. – 2016.
531. Hsu E., Moosavi L. Biochemistry, antithrombin III. – 2019.
532. Нехаев И. В. и др. Антитромбин III в интенсивной терапии //Тромбоз, гемостаз и реология. – 2015. – №. 1. – С. 13-21.
533. Croles F. N. et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian Meta-Analysis //Journal of Vascular Surgery: Venous and Lymphatic Disorders. – 2018. – Т. 6. – №. 2. – С. 280.
534. Ву А. Г. Б. Клиническое руководство Тица по лабораторным тестам //Ред. А. Ву (пер. с англ. В.В. Меньшикова). – 4-е издание–М., Лабора. – 2013.
535. Зозуля Н. И., Свирин П. В. Клинические рекомендации по диагностике и лечению редких коагулопатий: Наследственный дефицит факторов свертывания крови II, VII, X //НГО. – 2014. – Т. 35. – С. 19.
536. Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo Harrison's principles of internal medicine, 17th edition, 2009.
537. Harrington AM, Ward PC, Kroft SH. Iron deficiency anemia, beta-thalassemia minor, and anemia of chronic disease: a morphologic reappraisal / Am J Clin Pathol. 2008 Mar;129(3):466-71.
538. Lim W. Thrombotic Risk in the Antiphospholipid Syndrome. Semin Thromb Hemost 2014;40, pp.741–746.
539. Moore G.W. Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants. Semin Thromb Hemost. 2014; 40 (2), pp. 163-171.
540. CLSI H60-A Laboratory Testing for the Lupus Anticoagulant; Approved Guideline, 04/2014
541. Андрияшкин А. В. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбозных осложнений (ВТЭО) //Флебология. – 2015. – Т. 2. – №. 4. – С. 2.
542. Johnson E. D., Schell J. C., Rodgers G. M. The D-dimer assay //American journal of hematology. – 2019. – Т. 94. – №. 7. – С. 833-839.

543. Haybar H., Pezeshki S. M. S., Saki N. Evaluation of complete blood count parameters in cardiovascular diseases: An early indicator of prognosis? //Experimental and molecular pathology. – 2019. – Т. 110. – С. 104267.
544. Yenilmez E. D., Tuli A. Laboratory Approach to Anemia //Current Topics in Anemia. – IntechOpen, 2017.
545. Nigel Key. Practical hemostasis and thrombosis. – 2nd ed. – 2009.
546. Пшеничная К. И., Ивашикина Т. М., Зайдина М. В. Определение гемоглобина ретикулоцитов – современный подход к диагностике железодефицитных состояний у детей //Вопросы гематологии/онкологии и иммунопатологии в педиатрии. – 2020. – Т. 19. – №. 3. – С. 32-35.
547. Юшков Б. Г., Бриллиант С. А. Изоформы гемоглобина и гетерогенность эритроцитов. – 2021.
548. Chumakova S. P. et al. Features of the physiology of erythrocytes. Hemolysis and eryptosis //Russian journal of hematology and transfusiology. – 2018. – Т. 63. – №. 4. – С. 343-351.
549. Козинец Г., Стуклов Н., Тюрина Н. Учебник по гематологии. – Litres, 2022.
550. Соснин Д. Ю. Роль микроскопических исследований при подсчете тромбоцитов //Справочник заведующего КДЛ. – 2018. – №. 12. – С. 24-32.
551. A Manual of Laboratory and Diagnostic Tests, 9th Edition, by Frances Fischbach, Marshall B. Dunning III. Wolters Kluwer Health, 2015. Pages 174-175.
552. Клиническая лабораторная диагностика: национальное руководство: в 2 т. – Т. I / Под ред. В. В. Долгова, В. В. Меньшикова. – М.: ГЭОТАР-Медиа, 2012. С. 799-800.
553. Williams Hematology. 9th edition. By: Kenneth Kaushansky, Marshall Lichtman, Josef Prchal, Marcel M. Levi, Oliver Press, Linda Burns, Michael Caligiuri. McGraw-Hill Education, 2016. Pages 2222-2223.
554. Henry's Clinical Diagnosis and Management by Laboratory Methods, 23e by Richard A. McPherson MD MSc (Author), Matthew R. Pincus MD PhD (Author). St. Louis, Missouri : Elsevier, 2016. Pages 798-799.
555. Tektonidou M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults //Annals of the rheumatic diseases. – 2019. – Т. 78. – №. 10. – С. 1296-1304.
556. Burtis C. A., Ashwood E. R., Bruns D. E. Tietz textbook of clinical chemistry and molecular diagnostics-e-book. – Elsevier Health Sciences, 2012.
557. Mark T. Cunningham et al. Laboratory Diagnosis of Dysfibrinogenemia. Arch Pathol Lab Med. 2002 Apr; 126(4):499-505.
558. Chernecky C. C. Laboratory Tests and Diagnostic Procedures / C.C. Chernecky, B.J. Berger; 5th ed. - Saunder Elsevier, 2008.
559. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage incipient diabetic nephropathy. Diabetes 1983;32 Suppl 2:64–78.
560. Viberti GC, Mackintosh D, Bilous RW, et al. Proteinuria in diabetes mellitus: role of spontaneous and experimental variation of glycemia. Kidney International 1982;21:714–20.
561. Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry, 3rd ed. Philadelphia, PA: WB Saunders, 1999
562. Rosenstock J, Raskin P. Early diabetic nephropathy: assessment and potential therapeutic interventions. Diabetes Care 1986;9:529–45.

563. NKF K/DOQI Guidelines Web Site. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessments of kidney disease. 2002. Available at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p5_lab_g5.htm. Accessed October 11, 2007.
564. Sewell DL, Bove KE, Callihan DR, et al. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Third Edition (M29-A3). Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
565. Guder WG, Narayanan S, Wisser H, et al. List of analytes—preanalytical variables. Annex In: Samples: From the Patient to the Laboratory. Damstadt, Germany: GIT Verlag; 1996
566. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in Diabetes. *Diabetes Care* 2004;27(1):S79–83.
567. McIntosh A, Hutchinson A, Marshall S, et al. Background to enal disease in type 2 diabetes. In: *Clinical Guidelines for Type 2 Diabetes*. Sheffield, UK: University of Sheffield; 2001:27-36.
568. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 2003;26 Suppl 1:33–50.
569. Kennedy JW, Carey RN, Coolen RB, et al. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP9-A). Wayne, PA: The National Committee for Clinical Laboratory Standards, 1995.
570. NCCLS Document: “Procedures for the Collection of Arterial Blood Specimens; Approved Standard - Third Edition (1999)”.
571. EU-Dir 1999/11 Commission Directive of 8 March 1999 adapting to technical progress the principles of Good Laboratory Practice as specified in Council Directive 87/18/EEC.
572. Jakobs, D.S., Kasten, Jr., B.L., DeMott, W.R., Wolfson, W.L.: *Laboratory Test Handbook, Lexi-Comp and Williams & Wilkins Ed. (2nd Edition - 1990)*.
573. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): Approved Recommendation on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes - Part 9. IFCC Method for α -Amylase (1,4- α -D-Glucan 4-Glucanohydrolase, EC 3.2.1.1) - *Clin. Chem. Lab. Med.* 1998; 36(3): 185-203.
574. Rizzotti P. and Klein G.: Evaluation of a Specific Immunoinhibition Method for the Determination of Pancreatic α -Amylase - *Eur. J. Clin. Chem. Biochem.* Vol. 1994: 97-106.
575. Zilva JF, Pannall PR. Plasma proteins and immunoglobulins. *Clinical Chemistry in Diagnosis and Treatment*. London, England: Lloyd-Luke; 1979:305–29.
576. First MR. Renal function. In: Kaplan LA, Pesce AJ, editors. *Clinical Chemistry Theory, Analysis, and Correlation*. St. Louis, MO: CV Mosby; 1984:418.
577. Koumantakis G. Fluorescein interference with urinary creatinine and protein measurements. *Clin Chem* 1991;37(10):1799.
578. Tietz NW, editor. *Clinical Guide to Laboratory Tests*, 3rd ed. Philadelphia, PA: WB Saunders; 1995

579. US Pharmacopeial Convention, Inc. General notices. In: US Pharmacopeia National Formulary, 1995 ed (USP 23/NF 18). Rockville, MD: The US Pharmacopeial Convention, Inc; 1994:11.
580. Powers DM, Boyd JC, Glick MR, et al. Interference Testing in Clinical Chemistry; Proposed Guideline (EP7-P). Villanova, PA: The National Committee for Clinical Laboratory Standards, 1986.
581. Kennedy JW, Carey RN, Coolen RB, et al. Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline (EP5-A). Wayne, PA: The National Committee for Clinical Laboratory Standards, 1999.
582. Krouwer JS, Castaneda-Mendez K, Dawson JM, et al. Preliminary Evaluation of Quantitative Clinical Laboratory Methods; Approved Guideline (EP10-A). Wayne, PA: The National Committee for Clinical Laboratory Standards, 1998.
583. Jacobs DS, DeMott WR, Grady HJ, et al. Laboratory Test Handbook, 4th ed. Hudson, OH: Lexi-Comp; 1996
584. Malloy HT, Evelyn KA. The determination of bilirubin with the photoelectric colorimeter. *J Biol Chem* 1973;119:481–90.
585. Dennery PA, Seidman DS, Stevenson DK. Drug therapy: neonatal hyperbilirubinemia. *N Engl J Med* 2001;344(8):581–90.
586. Walters MI, Gerarde HW. An ultramicro method for the determination of conjugated and total bilirubin in serum or plasma. *Microchemical J* 1970;15:231–43.
587. Winsten S, Cehelyk B. A rapid micro diazo technique for measuring total bilirubin. *Clin Chim Acta* 1969;25(3):441–6.
588. Sasse EA, Doumas BT, Miller WG, et al. How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline—Second Edition (C28-A2). Wayne, PA: The National Committee for Clinical Laboratory Standards, 2000.
589. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. *Am J Nephrol*, 2007;27:30–5.
590. McPhaul L, Kershaw M, Tilque D, et al. A 2,4-dichlorophenyl diazonium-based method for total bilirubin without interference from indican in uremic sera. *Clin Chem*, 1985;31:1229–31.
591. Tholen DW, Kallner A, Kennedy JW, et al. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition (EP5-A2). Wayne, PA: The National Committee for Clinical Laboratory Standards, 2004.
592. Pinder RM, Brogden RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. *Drugs* 1977;13:81–123.
593. Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review. *Epilepsia* 1975;16:549–73.
594. Bruni J, Wilder BJ. Valproic acid. Review of a new antiepileptic drug. *Arch Neurol* 1979;36:393–8.
595. Koch-Weser J, Browne TR. Drug therapy: Valproic acid. *N Engl J Med* 1980;302:661–6.
596. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. *JAMA* 1980;244:785–8.

597. Sherard ES Jr, Steiman GS, Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial. *Neurology* 1980;30:31–5.
598. Redenbaugh JE, Sato S, Penry JK, et al. Sodium valproate: pharmacokinetics and effectiveness in treating intractable seizures. *Neurology* 1980;30:1–6.
599. Dren AT, Giardina WJ, Hagen NS. Valproic acid (Depakene): a review of pharmacological properties and clinical uses. In: Goldberg ME, editor. *Pharmacological and Biochemical Properties of Drug Substances*. Washington, DC: American Pharmaceutical Association; 1979:58-97.
600. Dasgupta A, Dean R, Saldana S, et al. Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. *Am J Clin Pathol* 1994;101:456–61.
601. Moyer TP. Therapeutic Drug Monitoring. In: Burtis CA, Ashwood ER, editors. *Tietz Textbook of Clinical Chemistry*, 3rd ed. Philadelphia, PA: WB Saunders; 1999:876.
602. Adams DJ, Luders H, Pippenger C. Sodium valproate in the treatment of intractable seizure disorders: a clinical and electroencephalographic study. *Neurology* 1978;28:152–7.
603. Tholen DW, Kroll M, Astles JR, et al. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (EP6-A). Wayne, PA: The National Committee for Clinical Laboratory Standards, 2003.
604. Theodorsen L, Stromme JH. Gamma-Glutamyl-3-carboxy-4-nitroanilide: the substrate of choice for routine determinations of gamma-glutamyl-transferase activity in serum? *Clin Chim Acta* 1976;72:205.
605. Thomas L. *Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results*. Frankfurt/Main, Germany: TH-Books Verlagsgesellschaft mbH; 1998:80–6.
606. Lester E. The clinical value of glycated haemoglobin and glycated plasma proteins. *Ann Clin Biochem* 1989;26(3):213–9.
607. Rochman H. Hemoglobin A1c and diabetes mellitus. *Ann Clin Lab Sci* 1980;10(2):111–5.
608. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329(14):977–86.
609. American Diabetes Association, Inc. Position Statement: Standards of Medical Care in Diabetes—2008. In: *Diabetes Care* 2008;31(Suppl 1):S12–S54.
610. Zander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemoglobin method, I. Description of the method. *Clin Chim Acta* 1984;136(1):83–93.
611. Goldstein DE, Wiedmeyer HM, England JD, et al. Recent advances in glycosylated hemoglobin measurements. *Crit Rev Clin Lab Sci* 1984;21(3):187–228.

612. Peacock I. Glycosylated haemoglobin: measurement and clinical use. *J Clin Pathol* 1984;37(8):841–51.
613. Horton BF, Huisman TH. Studies on the heterogeneity of haemoglobin, VII. Minor haemoglobin components in haematological diseases. *Br J Haematol* 1965;11:296–304.
614. Lind T, Cheyne GA. Effect of normal pregnancy upon the glycosylated haemoglobins. *Br J Obstet Gynaecol* 1979;86:210–3.
615. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. *Clin Chem* 2001;47(2):153–63.
616. Goodall I, Colman PG, Schneider HG, et al. Desirable performance standards for Hb A1c analysis—precision, accuracy and standardization. *Clin Chem Lab Med* 2007;45(8):1083–1097.
617. Weykamp CW, Penders TJ, Muskiet FA, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. *Clin Chem* 1993;39(8):1717–23.
618. FDA/CDRH ODE Guidance Documents. Review Criteria for Assessment of Glycohemoglobin (Glycated or Glycosylated) Hemoglobin In Vitro Diagnostic Devices. Food and Drug Administration Web site. Available at: <http://www.fda.gov/cdrh/ode/odecl658.html>. Accessed April 4, 2008.
619. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2002;48(3):436–72.
620. Gaffney PJ, et al. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP) I, Characterization and preliminary evaluation in plasma, *British Journal of Haematology*. 1988; 68: 83-90.
621. Palareti G. Fibrinogen/fibrin Degradation Products: Pathophysiology and Clinical Application, *Fibrinolysis*. 1993; 7: 60-61.
622. Gaffney PJ. The Occurrence and Clinical Relevance of Fibrin Fragments in Blood, *Annals New York Academy of Sciences*. 1983; 408: 407-423.
623. Higgins T. Novel chromogen for serum iron determinations. *Clin Chem* 1981;27(9):1619.
624. Artiss JD, Vinogradov S, Zak B. Spectrophotometric study of several sensitive reagents for serum iron. *Clin Biochem* 1981;14:311–5.
625. Helfer RE, Rodgeron DO. The effect of deferoxamine on the determination of serum iron and iron-binding capacity. *J Pediatr* 1966;68(5):804–6.
626. A-GENTR VP System Iron Package Insert. Abbott Park, IL: Abbott Laboratories; August 1996.
627. Kaplan LA, Pesce AJ, Kazmierczak SC. *Clinical Chemistry – Theory, Analysis, and Correlation*, 3rd ed. St. Louis, MO: Mosby, 1996:461–3.
628. McPherson RA, Bidkorphek EK, Castellani WJ, et al. *Analysis of Body Fluids in Clinical Chemistry; Approved Guideline (C49-A)*. Wayne, PA: The National Committee for Clinical Laboratory Standards, 2007.
629. Pesce AJ, Kaplan LA, editors. *Methods in Clinical Chemistry*. St. Louis, MO: CV Mosby, 1987:75.

630. Thomas L, editor. *Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results*. Frankfurt, Germany: TH-Books Verlagsgesellschaft mbH; 1998:366–74.
631. Jaffe M. Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. *Hoppe Seylers Z Physiol Chem* 1886;10:391–400
632. Folin O. Beitrag zur Chemie des Kreatinins und Kreatins Im Harn. *Hoppe Seylers Z Physiol Chem* 1904;41:223–42.
633. Fabiny DL, Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the Centrifichem. *Clin Chem* 1971;17:696–700.
634. Soldin S, Henderson L, Hill G. The effect of bilirubin and ketones on reaction rate methods for the measurement of creatinine. *Clin Biochem* 1978:82–6.
635. Rabinovitch A, Sarewitz SJ, Woodcock SM, et al. *Urinalysis and Collection Transportation, and Preservation of Urine Specimens; Approved Guideline—Second Edition (GP16-A2)*. Wayne, PA: The National Committee for Clinical Laboratory Standards, 2001.
636. Junge W, Wilke B, Halabi A, et al. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. *Clin Chim Acta* 2004;344:137–48.
637. *NCCLS Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard - Fifth Edition (H3-A5)*. Wayne, PA: The National Committee for Clinical Laboratory Standards, 2003.
638. Kaplan, L.A., Pesce, A.J.: “Clinical Chemistry”, Mosby Ed. (1996).
639. EU-Dir 1999/11 Commission Directive of 8 March 1999 adapting to technical progress the principles of Good Laboratory Practice as specified in Council Directive 87/18/EEC.
640. Amador E, Dorfman LE, Wacker WEC, et al. Serum lactic dehydrogenase activity: an analytical assessment of current assays. *Clin Chem* 1963;9:391.
641. Passey RB, Bee DE, Caffo A, et al. *Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guideline (EP6-P)*. Villanova, PA: The National Committee for Clinical Laboratory Standards, 1986.
642. Garber CC, Clark LW, Garrett PE, et al. *Preliminary Evaluation of Quantitative Clinical Laboratory Methods—Second Edition; Tentative Guideline (EP10-T2)*. Villanova, PA: The National Committee for Clinical Laboratory Standards, 1993.
643. Trivedi R, Rebar L, Berta E, et al. New enzymatic method for serum uric acid at 500 nm. *Clin Chem* 1978; 24(11):1908–11.
644. Kabasakalian P, Kalliney S, Wescott A. Determination of uric acid in serum, with use of uricase and tribromophenol-aminoantipyrine chromogen. *Clin Chem* 1973;19:522.
645. St. *Clinical Chemistry Theory, Analysis, and Correlation*, 3rd ed. St Louis, MO: 1996:501–2.
646. Kaplan LA, Pesce AJ, editors. *Clinical Chemistry Theory. Analysis. and Correlation*. 2nd ed. St. Louis. MO: CV Mosby; 1989:1059.

647. Dawnay AB, Hirst AD, Perry DE, et al. A critical assessment of current analytical methods for the routine assay of serum total protein and recommendations for their improvement. *Ann Clin Biochem* 1991;28:556-67.
648. Bakker AJ, Gorgels J, Draaisma J, et al. Simple method for correcting total protein in plasma for actual fibrinogen content. *Clin Chem* 1992;38(11):2221-3.
649. Deutsche Gesellschaft für Klinische Chemie. Proposal of Standard Methods for the determination of enzyme catalytic concentrations in serum and plasma at 37°C. II Cholinesterase (acylcholine acylhydrolase, EC 3.1.1.8). *Eur. J. Clin. Chem. Clin. Biochem* 30,163 (1992).
650. Volanakis JE. Human C-reactive protein: expression, structure, and function. *Mol Immunol* 2001;38:189-97.
651. Bienvenu J, Whicher JT, Aguzzi F. C-reactive protein, CRP. In: Ritchie RF, editor. *Serum Proteins in Clinical Medicine*, Vol 1. AACC, 1996:7.01-1-7.01-5.
652. Du Clos TW. Function of C-reactive protein. *Ann Med* 2000;32:274-8.
653. Henry JB. *Clinical Diagnosis and Management by Laboratory Methods*, 18th ed. Philadelphia, PA: WB Saunders; 1991:223.
654. Ledue TB, Collins MF, Ritchie RF. Development of immunoturbidimetric assays for fourteen human serum proteins on the Hitachi 912. *Clin Chem Lab Med* 2002;40(5):520-8.
655. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal* 1999;13:273-9.
656. Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. *J Cardiovasc Risk* 2000;7(5):339-45.
657. Forrester JS. Triglycerides: risk factor or fellow traveler? *Curr Opin Cardiol* 2001;16:261-4.
658. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin Chem* 1982;28:2077-80.
659. McGowan MW, Artiss JD, Strandbergh DR, et al. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. *Clin Chem* 1983;29:538-42.
660. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
661. Flegg HM. An investigation of the determination of serum cholesterol by an enzymatic method. *Ann Clin Biochem* 1973;10:79-84.
662. Richmond W. Preparation and properties of a cholesterol oxidase from *Nocardia* sp. and its application to the enzymatic assay of total cholesterol in serum. *Clin Chem* 1973;19(12):1350-6.
663. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. *Clin Chem* 1974;20(4):470-5.
664. Roeschlau P, Bernt E, Gruber WA. Enzymatic determination of total cholesterol in serum. *Z Klin Chem Klin Biochem* 1974;12:226.

665. American Academy of Pediatrics, Committee on Nutrition. Cholesterol in childhood. *Pediatrics* 1998;101(1):141–7.
666. King EJ, Armstrong AR. A convenient method for determining serum and bile phosphatase activity. *Can Med Assoc J* 1934;31:376–81.
667. Tietz NW, Burtis CA, Duncan P, et al. A reference method for measurement of alkaline phosphatase activity in human serum. *Clin Chem* 1983;29(5):751–6.